Exporter
Liste modèle des médicaments essentiels
Trouvé 1312 recommandations pour 635 médicaments et 135 équivalents thérapeutiques
Les médicaments retirés et les demandes rejetées ne sont pas indiqués. Les afficher.
-
BCG vaccine Informations générales
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Japanese encephalitis vaccine Informations générales
SectionRecommendations for certain regions- All vaccines should comply with the WHO requirements for biological substances.
-
Medicines for COVID-19 Informations générales
SectionMedicines for COVID-19- Refer to WHO living guidelines
Indications -
Abacavir Informations générales
SectionAntiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors- Oral > Solid: 300 mg tablet (as sulfate)
-
Abacavir + lamivudine Informations générales
SectionFixed-dose combinations of antiretrovirals- Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)
-
Abiraterone Informations générales
SectionHormones and antihormones- Oral > Solid: 250 mg; 500 mg
Indications -
Acamprosate calcium Informations générales
SectionMedicines for alcohol use disorders- Oral > Solid > tablet: 333 mg
Indications -
Acetazolamide Informations générales
SectionOphthalmological preparations > Miotics and antiglaucoma medicines- Oral > Solid: 250 mg
Indications -
Acetic acid Informations générales
SectionEar, nose and throat medicines [c]- Local > Otological > drops: 2% in alcohol
Indications -
Acetylcysteine Informations générales
SectionAntidotes and other substances used in poisonings > Specific- Parenteral > General injections > IV: 200 mg per mL in 10 mL ampoule
- Oral > Liquid: 10%; 20%
-
Acetylsalicylic acid Informations générales
SectionAntimigraine medicines > For treatment of acute attack- Oral > Solid: 300 to 500 mg
IndicationsSectionAnti-platelet medicines- Oral > Solid: 100 mg
IndicationsSectionMedicines for juvenile joint diseases- Oral > Solid: 100 to 500 mg
- Local > Rectal > Suppository: 50 to 150 mg
SectionNon-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)- Oral > Solid: 100 to 500 mg
- Local > Rectal > Suppository: 50 to 150 mg
Indications -
Acetylsalicylic acid + atorvastatin + ramipril Informations générales
SectionFixed-dose combinations for prevention of atherosclerotic cardiovascular disease- Oral > Solid > tablet: 100 mg + 20 mg + 2.5 mg; 100 mg + 20 mg + 5 mg; 100 mg + 20 mg + 10 mg; 100 mg + 40 mg + 2.5 mg; 100 mg + 40 mg + 5 mg; 100 mg + 40 mg + 10 mg
-
Acetylsalicylic acid + simvastatin + ramipril + atenolol + hydrochlorothiazide Informations générales
SectionFixed-dose combinations for prevention of atherosclerotic cardiovascular disease- Oral > Solid > tablet: 100 mg + 20 mg + 5 mg + 50 mg + 12.5 mg
-
Aciclovir Informations générales
SectionAntiherpes medicines- Parenteral > General injections > IV: 250 mg in vial powder for injection (as sodium salt)
- Oral > Liquid: 200 mg per 5 mL
- Oral > Solid: 200 mg tablet
IndicationsSectionOphthalmological preparations > Anti-infective agents- Local > Ophthalmological > Ointment: 3% w/w
Indications -
Aclidinium Informations générales
SectionAntiasthmatic and medicines for chronic obstructive pulmonary diseaseIndicationsTherapeutic equivalent to tiotropium bromide pour Chronic obstructive pulmonary disease -
Activated charcoal Informations générales
SectionAntidotes and other substances used in poisonings > Non-specific- Oral > Other: powder
-
Adalimumab Informations générales
SectionImmunomodulators for non-malignant disease- Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL
SectionMedicines for juvenile joint diseases- Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL
Indications -
Afatinib Informations générales
SectionTargeted therapiesIndicationsTherapeutic equivalent to erlotinib pour Other specified malignant neoplasms of bronchus or lung -
Albendazole Informations générales
SectionIntestinal anthelminthics- Oral > Solid > tablet: 400 mg (chewable, scored)
SectionCysticidal medicines- Oral > Solid > tablet: 400 mg (chewable, scored); 200 mg (chewable)
SectionAntifilarials- Oral > Solid > tablet: 400 mg (chewable, scored)
Indications -
Alcohol based hand rub Informations générales
SectionDisinfectants- Local > Topical > Solution: 80% v/v ethanol; 75% v/v isopropyl alcohol
Indications -
All-trans retinoic acid Informations générales
SectionTargeted therapies- Oral > Solid: 10 mg capsule
-
Allopurinol Informations générales
SectionMedicines used to treat gout- Oral > Solid: 100 mg
IndicationsSectionSupportive medicines- Oral > Solid: 100 mg; 300 mg
Indications -
Alteplase Informations générales
SectionThrombolytic medicines- Parenteral > General injections > IV: 10 mg in vial powder for injection; 20 mg in vial powder for injection; 50 mg in vial powder for injection
Indications -
Amidotrizoate Informations générales
SectionDiagnostic agents > Radiocontrast media- Parenteral > General injections > unspecified: 140 to 420 mg iodine per mL in 20 mL ampoule (as sodium or meglumine salt)
Indications -
Amikacin Informations générales
SectionOphthalmological preparations > Anti-infective agentsIndicationsTherapeutic equivalent to gentamicin pour Other specified conjunctivitis Therapeutic equivalent to gentamicin pour Infectious blepharitisSectionAntituberculosis medicines- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
IndicationsSectionAccess group antibiotics- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate)
- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
IndicationsPremier choix
Neutropenia (high-risk) co-prescrite avec cefotaxime Inflammatory and other diseases of prostate (severe) co-prescrite avec cefotaxime Acute pyelonephritis (severe) co-prescrite avec ceftriaxone Inflammatory and other diseases of prostate (severe) co-prescrite avec ceftriaxone Acute pyelonephritis (severe)Second choix
co-prescrite avec cloxacillin Sepsis without septic shock -
Amiloride Informations générales
-
Amiodarone Informations générales
SectionAntiarrhythmic medicines- Parenteral > General injections > IV: 50 mg per mL in 3 ampoule (hydrochloride)
- Oral > Solid: 100 mg (hydrochloride); 200 mg (hydrochloride); 400 mg (hydrochloride)
Indications -
Amitriptyline Informations générales
SectionMedicines for other common symptoms in palliative care- Oral > Solid: 25 mg; 10 mg; 75 mg
IndicationsSectionMedicines for depressive disorders- Oral > Solid: 25 mg; 75 mg
Indications -
Amlodipine Informations générales
SectionAntihypertensive medicines- Oral > Solid: 5 mg (as maleate, mesylate or besylate)
Indications -
Amodiaquine Informations générales
SectionAntimalarial medicines > For curative treatment- Oral > Solid: 153 mg (as hydrochloride); 200 mg (as hydrochloride)
-
Amodiaquine + sulfadoxine + pyrimethamine Informations générales
SectionAntimalarial medicines > For chemoprevention- Oral > Solid: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] dispersible tablets in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] dispersible tablets in co-package
Indications -
Amoxicillin Informations générales
SectionAccess group antibiotics- Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
- Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection
- Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)
- Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)
- Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate)
IndicationsPremier choix
Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Acute malnutrition in infants, children or adolescents (uncomplicated) [children] Acute malnutrition in infants, children or adolescents (complicated) [children] Acute pharyngitis Chronic obstructive pulmonary disease with acute exacerbation Periapical abscess without sinus Acute otitis media Acute sinusitis co-prescrite avec gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec gentamicin Sepsis without septic shockSecond choix
Bacterial meningitis -
Amoxicillin + clavulanic acid Informations générales
SectionAccess group antibiotics- Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
- Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
- Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)
IndicationsPremier choix
Peritoneal abscess (mild-moderate) Neutropenia (low-risk) Other specified pneumonia (Hospital-acquired pneumonia) Infectious cystitis Chronic obstructive pulmonary disease with acute exacerbation Peritonitis (mild-moderate) Acute sinusitis Bacterial cellulitis, erysipelas or lymphangitis Bacterial pneumonia (Community-acquired pneumonia - severe) [children]SectionAntituberculosis medicines- Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)
Indications -
Amphotericin B Informations générales
SectionAntifungal medicines- Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)
SectionAntileishmaniasis medicines- Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)
Indications -
Ampicillin Informations générales
SectionAccess group antibiotics- Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
IndicationsPremier choix
co-prescrite avec gentamicin Peritoneal abscess (severe) co-prescrite avec gentamicin Sepsis without septic shock co-prescrite avec gentamicin Peritoneal abscess (mild-moderate) co-prescrite avec gentamicin Peritonitis (severe) co-prescrite avec gentamicin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec gentamicin Peritonitis (mild-moderate) co-prescrite avec gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children]Second choix
Bacterial meningitis -
Anastrozole Informations générales
SectionHormones and antihormones- Oral > Solid: 1 mg tablet
-
Anidulafungin Informations générales
SectionAntifungal medicinesIndicationsTherapeutic equivalent to micafungin pour Systemic or invasive candidosis -
Ansuvimab Informations générales
SectionMedicines for Ebola virus disease- Parenteral > General injections > IV: 400 mg powder for injection
Indications -
Anti-D immunoglobulin Informations générales
SectionHuman immunoglobulins- Parenteral > General injections > IV: 250 µg in single-dose vial
- Parenteral > General injections > IM: 250 µg in single-dose vial
-
Anti-rabies immunoglobulin Informations générales
SectionHuman immunoglobulins- Parenteral > General injections > IM: 150 IU per mL in vial
- Parenteral > Locoregional injections > Other: 150 IU per mL in vial
Indications -
Anti-rabies virus monoclonal antibodies Informations générales
SectionImmunologicals > Sera, immunoglobulins and monoclonal antibodies- Parenteral > Locoregional injections > Intradermal: 40 IU per mL in 1.25 mL vial (human); 40 IU per mL in 2.5 mL vial (human); 100 IU per mL in 2.5 mL vial (human); 300 IU per mL in 10 mL vial (murine); 600 IU per mL in 1 mL vial (murine); 600 IU per mL in 2.5 mL vial (murine); 600 IU per mL in 5 mL vial (murine)
Indications -
Anti-tetanus immunoglobulin Informations générales
SectionHuman immunoglobulins- Parenteral > General injections > IM: 500 IU in vial
Indications -
Antivenom immunoglobulin Informations générales
SectionImmunologicals > Sera, immunoglobulins and monoclonal antibodies- Parenteral > General injections > IV:
-
Apixaban Informations générales
SectionMedicines affecting coagulationIndicationsTherapeutic equivalent to dabigatran pour Venous thromboembolism Therapeutic equivalent to dabigatran pour Other specified atrial fibrillation -
Aprepitant Informations générales
SectionAntiemetic medicines- Oral > Liquid: 125 mg powder for oral suspension (in sachet)
- Oral > Solid: 80 mg; 125 mg; 165 mg
Indications -
Aripiprazole Informations générales
SectionMedicines for psychotic disordersIndicationsTherapeutic equivalent to risperidone pour Schizophrenia or other primary psychotic disorders -
Arsenic trioxide Informations générales
SectionCytotoxic medicines- Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion
-
Artemether Informations générales
SectionAntimalarial medicines > For curative treatment- Parenteral > General injections > IM: 80 mg per mL in 1 mL ampoule (oily injection)
-
Artemether + lumefantrine Informations générales
SectionAntimalarial medicines > For curative treatment- Oral > Solid: 20 mg + 120 mg tablet; 20 mg + 120 mg dispersible tablet
-
Artesunate Informations générales
SectionAntimalarial medicines > For curative treatment- Parenteral > General injections > IV: 60 mg in ampoule containing anhydrous artesunic acid with a separate ampoule of 5% sodium bicarbonate solution
- Oral > Solid: 50 mg tablet
- Local > Rectal > Other: 50 mg capsules; 200 mg capsules; 100 mg capsules
-
Artesunate + amodiaquine Informations générales
SectionAntimalarial medicines > For curative treatment- Oral > Solid: 25 mg + 67.5 mg tablet; 50 mg + 135 mg tablet; 100 mg + 270 mg tablet
-
Artesunate + mefloquine Informations générales
SectionAntimalarial medicines > For curative treatment- Oral > Solid: 25 mg + 55 mg tablet; 100 mg + 220 mg tablet
-
Artesunate + pyronaridine tetraphosphate Informations générales
SectionAntimalarial medicines > For curative treatment- Oral > Solid: 60 mg + 180 mg tablet; 20 mg + 60 mg granules
-
Ascorbic acid Informations générales
SectionVitamins and minerals- Oral > Solid: 50 mg
Indications -
Asparaginase Informations générales
SectionCytotoxic medicines- Parenteral > General injections > unspecified: 10000 IU in vial powder for injection
Indications -
Atazanavir + ritonavir Informations générales
SectionAntiretrovirals > Protease inhibitors- Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)
-
Atenolol Informations générales
SectionAntihypertensive medicinesIndicationsTherapeutic equivalent to bisoprolol pour Essential hypertension -
Atoltivimab + maftivimab + odesivimab Informations générales
SectionMedicines for Ebola virus disease- Parenteral > General injections > IV: 241.7 mg + 241.7 mg + 241.7 mg in 14.5 mL vial
Indications -
Atorvastatin Informations générales
SectionLipid-lowering agentsIndicationsTherapeutic equivalent to simvastatin pour Mixed hyperlipidaemia Therapeutic equivalent to simvastatin pour Coronary atherosclerosis -
Atorvastatin + perindopril + amlodipine Informations générales
SectionFixed-dose combinations for prevention of atherosclerotic cardiovascular disease- Oral > Solid > tablet: 20 mg + 5 mg + 5 mg; 20 mg + 10 mg + 10 mg; 40 mg + 5 mg + 5 mg; 40 mg + 10 mg + 10 mg
-
Atracurium Informations générales
SectionMuscle relaxants (peripherally-acting) and cholinesterase inhibitors- Parenteral > General injections > IV: 10 mg per mL (besylate)
Indications -
Atropine Informations générales
SectionAntidotes and other substances used in poisonings > Specific- Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (atropine sulfate)
SectionPreoperative medication and sedation for short-term procedures- Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (atropine sulfate)
SectionDiagnostic agents > Ophthalmic medicinesIndicationsTherapeutic equivalent to tropicamide pour Cycloplegic drugSectionOphthalmological preparations > Mydriatics- Local > Ophthalmological > Solution (eye drops): 0.1% (sulfate); 0.5% (sulfate); 1% (sulfate)
Indications -
Azathioprine Informations générales
SectionImmunomodulators for non-malignant disease- Parenteral > General injections > IV: 50 mg in vial powder for injection (as sodium salt); 100 mg in vial powder for injection (as sodium salt)
- Oral > Liquid: 10 mg per mL
- Oral > Solid > tablet: 25 mg; 50 mg (scored)
SectionDisease-modifying anti-rheumatic drugs (DMARDs)- Oral > Solid > tablet: 50 mg (scored)
-
Azithromycin Informations générales
SectionOphthalmological preparations > Anti-infective agents- Local > Ophthalmological > Solution (eye drops): 1.5% eye drops
IndicationsSectionWatch group antibiotics- Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid
- Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)
IndicationsPremier choix
Chlamydia trachomatis Typhoid fever Yaws Paratyphoid fever Cholera Cholera [children] Trachoma co-prescrite avec ceftriaxone Gonococcal infectionSecond choix
Infectious gastroenteritis or colitis without specification of infectious agent co-prescrite avec cefixime Gonococcal infection -
Barium sulfate Informations générales
SectionDiagnostic agents > Radiocontrast media- Oral > Liquid: Aqueous suspension
Indications -
Beclometasone Informations générales
SectionAntiasthmatic and medicines for chronic obstructive pulmonary diseaseIndicationsTherapeutic equivalent to budesonide pour Asthma -
Beclometasone + formoterol Informations générales
SectionAntiasthmatic and medicines for chronic obstructive pulmonary diseaseIndicationsTherapeutic equivalent to budesonide + formoterol pour Asthma -
Bedaquiline Informations générales
SectionAntituberculosis medicines- Oral > Solid: 100 mg tablet; 20 mg tablet
Indications -
Bendamustine Informations générales
SectionCytotoxic medicines- Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL
-
Benzathine benzylpenicillin Informations générales
SectionAccess group antibiotics- Parenteral > General injections > IM: 1.2 million IU in vial (≈ 900 mg) powder for injection; 2.4 million IU in vial (≈ 1.8 g) powder for injection
-
Benznidazole Informations générales
SectionAmerican trypanosomiasis- Oral > Solid > tablet: 100 mg (scored); 50 mg (scored); 12.5 mg
Indications -
Benzoyl peroxide Informations générales
SectionDermatological medicines > Medicines affecting skin differentiation and proliferation- Local > Topical > Cream: 5%
- Local > Topical > Lotion: 5%
Indications -
Benzyl benzoate Informations générales
SectionDermatological medicines > Scabicides and pediculicides- Local > Topical > Lotion: 25%
Indications -
Benzylpenicillin Informations générales
SectionAccess group antibiotics- Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
IndicationsPremier choix
Congenital syphilis [children] Syphilis co-prescrite avec gentamicin Sepsis without septic shock co-prescrite avec gentamicin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children]Second choix
Bacterial meningitis -
Betamethasone Informations générales
SectionDermatological medicines > Anti-inflammatory and antipruritic medicines- Local > Topical > Cream: 0.1% (as valerate)
- Local > Topical > Ointment: 0.1% (as valerate)
-
Bevacizumab Informations générales
SectionOphthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations- Parenteral > Locoregional injections > Intravitreal: 25 mg per mL
Indications -
Bicalutamide Informations générales
SectionHormones and antihormones- Oral > Solid: 50 mg
Indications -
Biperiden Informations générales
SectionMedicines for parkinsonism- Parenteral > General injections > IV: 5 mg per mL in 1 mL ampoule (lactate)
- Oral > Solid: 2 mg tablet (hydrochloride)
Indications -
Bisacodyl Informations générales
SectionLaxativesIndicationsTherapeutic equivalent to senna pour Constipation -
Bisoprolol Informations générales
SectionAntianginal medicines- Oral > Solid: 1.25 mg; 5 mg
IndicationsSectionMedicines used in heart failure- Oral > Solid: 1.25 mg; 5 mg
IndicationsSectionAntihypertensive medicines- Oral > Solid: 1.25 mg; 5 mg
IndicationsSectionAntiarrhythmic medicines- Oral > Solid: 1.25 mg; 5 mg
Indications -
Bleomycin Informations générales
SectionCytotoxic medicines- Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)
-
Bortezomib Informations générales
SectionTargeted therapies- Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection
Indications -
Bromocriptine Informations générales
SectionMedicines for disorders of the pituitary hormone systemIndicationsTherapeutic equivalent to cabergoline pour Other specified benign neoplasm of endocrine glands -
Budesonide Informations générales
SectionAntiasthmatic and medicines for chronic obstructive pulmonary disease- Respiratory > Inhalation > aerosol: 100 µg per dose; 200 µg per dose
IndicationsSectionEar, nose and throat medicines [c]- Local > Nasal > Spray: 100 µg per dose
Indications -
Budesonide + formoterol Informations générales
SectionAntiasthmatic and medicines for chronic obstructive pulmonary disease- Respiratory > Inhalation > dry powder: 100 µg + 6 µg per dose; 200 µg + 6 µg per dose
Indications -
Budesonide + salmeterol Informations générales
SectionAntiasthmatic and medicines for chronic obstructive pulmonary diseaseIndicationsTherapeutic equivalent to budesonide + formoterol pour Asthma -
Bumetanide Informations générales
SectionMedicines used in heart failureIndicationsTherapeutic equivalent to furosemide pour Heart failureSectionDiureticsIndicationsTherapeutic equivalent to furosemide pour Anuria or oliguria Therapeutic equivalent to furosemide pour Oedema -
Bupivacaine Informations générales
SectionLocal anaesthetics- Parenteral > Locoregional injections > Spinal anaesthesia: 0.5% in 4 mL ampoule (hydrochloride) + 7.5% glucose solution
- Parenteral > General injections > unspecified: 0.25% in vial (hydrochloride); 0.5% in vial (hydrochloride)
Indications -
Buprenorphine Informations générales
SectionMedicines for opioid use disordersIndicationsTherapeutic equivalent to methadone pour Opioid dependence -
Bupropion Informations générales
SectionMedicines for nicotine use disorders- Oral > Solid: 150 mg sustained-release (hydrochloride)
Indications -
Cabergoline Informations générales
SectionMedicines for disorders of the pituitary hormone system- Oral > Solid > tablet: 0.5 mg; 1 mg
-
Caffeine citrate Informations générales
SectionMedicines administered to the neonate [c]- Parenteral > General injections > IV: 20 mg per mL (equivalent to 10 mg caffeine base per mL)
- Oral > Liquid: 20 mg per mL (equivalent to 10 mg caffeine base per mL)
Indications -
Calamine Informations générales
SectionDermatological medicines > Anti-inflammatory and antipruritic medicines- Local > Topical > Lotion:
Indications -
Calcipotriol Informations générales
SectionDermatological medicines > Medicines affecting skin differentiation and proliferation- Local > Topical > Cream: 50 µg per mL (0.005%)
- Local > Topical > Lotion: 50 µg per mL (0.005%)
- Local > Topical > Ointment: 50 µg per mL (0.005%)
Indications -
Calcitriol Informations générales
SectionDermatological medicines > Medicines affecting skin differentiation and proliferationIndicationsTherapeutic equivalent to calcipotriol pour Psoriasis of unspecified type -
Calcium Informations générales
SectionVitamins and minerals- Oral > Solid: 500 mg (elemental calcium)
Indications -
Calcium folinate (leucovorin calcium) Informations générales
SectionCytotoxic medicines- Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule; 7.5 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
- Oral > Solid > tablet: 15 mg; 5 mg; 25 mg
-
Calcium gluconate Informations générales
SectionAntidotes and other substances used in poisonings > Specific- Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
IndicationsSectionVitamins and minerals- Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
Indications -
Canagliflozin Informations générales
SectionOral hypoglycaemic agentsIndicationsTherapeutic equivalent to empagliflozin pour Type 2 diabetes mellitus -
Capecitabine Informations générales
SectionCytotoxic medicines- Oral > Solid > tablet: 150 mg; 500 mg
-
Carbachol Informations générales
SectionOphthalmological preparations > Miotics and antiglaucoma medicinesIndicationsTherapeutic equivalent to pilocarpine pour Acute angle closure with pupillary block Therapeutic equivalent to pilocarpine pour Ocular hypertension Therapeutic equivalent to pilocarpine pour Primary open-angle glaucoma -
Carbamazepine Informations générales
SectionMedicines for bipolar disorders- Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 400 mg
IndicationsSectionAntiseizure medicines- Oral > Liquid: 100 mg per 5 mL
- Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 100 mg (chewable); 200 mg (chewable); 400 mg (scored)
Indications -
Carbetocin Informations générales
SectionUterotonics- Parenteral > General injections > IV: 100 µg per mL (heat stable)
Indications -
Carbimazole Informations générales
SectionThyroid hormones and antithyroid medicinesIndicationsTherapeutic equivalent to methimazole pour Thyrotoxicosis -
Carboplatin Informations générales
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL
IndicationsOther specified gliomas of brain Other specified carcinomas of ovary Retinoblastoma Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of nasopharynx Malignant neoplasms of kidney, except renal pelvis Malignant neoplasms of breast Osteosarcoma of bone and articular cartilage of unspecified sites Malignant neoplasms of lip, oral cavity or pharynx Malignant neoplasms of cervix uteri Other specified malignant neoplasms of the ovary Germ cell tumour of testis -
Carvedilol Informations générales
SectionAntianginal medicinesIndicationsTherapeutic equivalent to bisoprolol pour Angina pectorisSectionMedicines used in heart failureIndicationsTherapeutic equivalent to bisoprolol pour Heart failureSectionAntihypertensive medicinesIndicationsTherapeutic equivalent to bisoprolol pour Essential hypertensionSectionAntiarrhythmic medicinesIndicationsTherapeutic equivalent to bisoprolol pour Cardiac arrhythmia -
Caspofungin Informations générales
SectionAntifungal medicinesIndicationsTherapeutic equivalent to micafungin pour Systemic or invasive candidosis -
Cefalexin Informations générales
SectionAccess group antibiotics- Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
- Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)
- Oral > Solid > dispersible tablet: 125 mg; 250 mg
-
Cefazolin Informations générales
SectionAccess group antibiotics- Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection
IndicationsPremier choix
Other specified prophylactic measures co-prescrite avec metronidazole Other specified prophylactic measures -
Cefiderocol Informations générales
SectionReserve group antibiotics- Parenteral > General injections > IV: 1 g in vial (as sulfate tosylate) powder for injection
-
Cefixime Informations générales
SectionWatch group antibiotics- Oral > Liquid: 100 mg per 5 mL powder for oral liquid
- Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)
IndicationsSecond choix
Infectious gastroenteritis or colitis without specification of infectious agent co-prescrite avec azithromycin Gonococcal infection -
Cefotaxime Informations générales
SectionWatch group antibiotics- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
IndicationsPremier choix
Other specified pneumonia (Hospital-acquired pneumonia) Bacterial meningitis Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec amikacin Inflammatory and other diseases of prostate (severe) co-prescrite avec amikacin Acute pyelonephritis (severe) co-prescrite avec clarithromycin Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescrite avec metronidazole Peritonitis (severe) co-prescrite avec metronidazole Peritonitis (mild-moderate) co-prescrite avec metronidazole Peritoneal abscess (severe) co-prescrite avec metronidazole Peritoneal abscess (mild-moderate) -
Ceftazidime Informations générales
SectionWatch group antibiotics- Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection
-
Ceftazidime + avibactam Informations générales
SectionReserve group antibiotics- Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection
-
Ceftolozane + tazobactam Informations générales
SectionReserve group antibiotics- Parenteral > General injections > IV: 1 g + 0.5 g powder for injection
Indications -
Ceftriaxone Informations générales
SectionWatch group antibiotics- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
- Parenteral > Locoregional injections > Intravitreal: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 2 g in vial; 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
IndicationsPremier choix
Typhoid fever Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Paratyphoid fever Other specified pneumonia (Hospital-acquired pneumonia) Bacterial meningitis co-prescrite avec amikacin Acute pyelonephritis (severe) co-prescrite avec amikacin Inflammatory and other diseases of prostate (severe) co-prescrite avec azithromycin Gonococcal infection co-prescrite avec clarithromycin Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescrite avec metronidazole Necrotising fasciitis co-prescrite avec metronidazole Peritonitis (mild-moderate) co-prescrite avec metronidazole Peritonitis (severe) co-prescrite avec metronidazole Peritoneal abscess (mild-moderate) co-prescrite avec metronidazole Peritoneal abscess (severe) co-prescrite avec vancomycin Endophthalmitis -
Cefuroxime Informations générales
SectionWatch group antibiotics- Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection
-
Certolizumab pegol Informations générales
SectionImmunomodulators for non-malignant diseaseIndicationsTherapeutic equivalent to adalimumab pour Axial spondyloarthritis Therapeutic equivalent to adalimumab pour Crohn disease site Therapeutic equivalent to adalimumab pour Rheumatoid arthritisSectionMedicines for juvenile joint diseasesIndicationsTherapeutic equivalent to adalimumab pour Juvenile idiopathic arthritis -
Cetirizine Informations générales
SectionAntiallergics and medicines used in anaphylaxisIndicationsTherapeutic equivalent to loratadine pour Allergic or hypersensitivity conditions of unspecified type -
Chlorambucil Informations générales
SectionCytotoxic medicines- Oral > Solid: 2 mg tablet
-
Chloramphenicol Informations générales
SectionAccess group antibiotics- Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)
- Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection
-
Chlorhexidine Informations générales
SectionMedicines administered to the neonate [c]- Local > Topical > Solution: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)
- Local > Topical > Gel: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)
IndicationsSectionAntiseptics- Local > Topical > Solution: 5% (digluconate) for dilution
Indications -
Chlorine base compound Informations générales
SectionDisinfectants- Local > Topical > Powder: 0.1% available chlorine for solution
- Local > Topical > Liquid: 0.1% available chlorine for solution
- Local > Topical > Solid: 0.1% available chlorine for solution
Indications -
Chloroquine Informations générales
SectionAntimalarial medicines > For curative treatment- Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
- Oral > Solid: 150 mg tablet (as phosphate or sulfate); 100 mg tablet (as phosphate or sulfate)
IndicationsSectionAntimalarial medicines > For chemoprevention- Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
- Oral > Solid: 150 mg tablet (as phosphate or sulfate)
SectionDisease-modifying anti-rheumatic drugs (DMARDs)- Oral > Solid: 100 mg tablet (as phosphate or sulfate); 150 mg tablet (as phosphate or sulfate)
Indications -
Chlorothiazide Informations générales
SectionAntihypertensive medicinesIndicationsTherapeutic equivalent to hydrochlorothiazide pour Essential hypertensionSectionMedicines used in heart failureIndicationsTherapeutic equivalent to hydrochlorothiazide pour Heart failure -
Chloroxylenol Informations générales
SectionDisinfectants- Local > Topical > Solution: 4.8%
Indications -
Chlorpromazine Informations générales
SectionMedicines for psychotic disorders- Oral > Liquid: 25 mg per 5 mL (hydrochloride)
- Oral > Solid: 100 mg (hydrochloride)
IndicationsTherapeutic equivalent to haloperidol pour Schizophrenia or other primary psychotic disorders -
Chlortalidone Informations générales
SectionAntihypertensive medicinesIndicationsTherapeutic equivalent to hydrochlorothiazide pour Essential hypertensionSectionMedicines used in heart failureIndicationsTherapeutic equivalent to hydrochlorothiazide pour Heart failure -
Chlortetracycline Informations générales
SectionOphthalmological preparations > Anti-infective agentsIndicationsTherapeutic equivalent to tetracycline pour Other specified conjunctivitis Therapeutic equivalent to tetracycline pour Infectious keratitis Therapeutic equivalent to tetracycline pour Infectious blepharitis Therapeutic equivalent to tetracycline pour Trachoma -
Cholera vaccine Informations générales
SectionRecommendations for some high-risk populations- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Ciclesonide Informations générales
SectionAntiasthmatic and medicines for chronic obstructive pulmonary diseaseIndicationsTherapeutic equivalent to budesonide pour Asthma -
Ciclosporin Informations générales
SectionImmunomodulators for non-malignant disease- Parenteral > General injections > IV: 50 mg per mL in 1 mL ampoule concentrate for injection
- Oral > Liquid: 100 mg per mL
- Oral > Solid > capsule: 25 mg
-
Ciprofloxacin Informations générales
SectionEar, nose and throat medicines [c]- Local > Otological > drops: 0.3% (as hydrochloride)
IndicationsSectionWatch group antibiotics- Parenteral > General injections > IV: 2 mg per mL (as hyclate)
- Oral > Liquid: 250 mg per 5 mL (anhydrous)
- Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride)
- Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride)
IndicationsPremier choix
Neutropenia (low-risk) Inflammatory and other diseases of prostate (mild to moderate) Typhoid fever Paratyphoid fever Infectious gastroenteritis or colitis without specification of infectious agent Acute pyelonephritis (mild to moderate)Second choix
Cholera Cholera [children] co-prescrite avec metronidazole Peritoneal abscess (mild-moderate) co-prescrite avec metronidazole Peritonitis (mild-moderate) -
Cisplatin Informations générales
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL
IndicationsOther specified gliomas of brain Other specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of nasopharynx Germ cell tumour of testis Osteosarcoma of bone and articular cartilage of unspecified sites Malignant neoplasms of lip, oral cavity or pharynx Malignant neoplasms of cervix uteri -
Cladribine Informations générales
SectionMedicines for multiple sclerosis- Oral > Solid > tablet: 10 mg
Indications -
Clarithromycin Informations générales
SectionWatch group antibiotics- Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid
- Parenteral > General injections > unspecified: 500 mg in vial powder for injection
- Oral > Solid > dosage form: 500 mg; 250 mg
- Oral > Solid > dosage form: 500 mg
IndicationsPremier choix
co-prescrite avec cefotaxime Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescrite avec ceftriaxone Bacterial pneumonia (Community-acquired pneumonia - severe)Second choix
Acute pharyngitis co-prescrite avec amoxicillin + clavulanic acid Bacterial pneumonia (Community-acquired pneumonia - severe)Autres indications -
Clindamycin Informations générales
SectionAccess group antibiotics- Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate)
- Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride)
- Oral > Solid: 150 mg (as hydrochloride)
-
Clofazimine Informations générales
SectionAntituberculosis medicines- Oral > Solid: 100 mg; 50 mg
IndicationsSectionAntileprosy medicines- Oral > Solid: 100 mg; 50 mg
Indications -
Clomifene Informations générales
SectionOvulation inducers- Oral > Solid: 50 mg (citrate)
-
Clomipramine Informations générales
SectionMedicines for obsessive compulsive disorders- Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)
Indications -
Clopidogrel Informations générales
SectionAnti-platelet medicines- Oral > Solid: 75 mg; 300 mg
-
Clotrimazole Informations générales
SectionAntifungal medicines- Local > Topical > Other: 1% vaginal cream; 10% vaginal cream; 100 mg vaginal tablet; 500 mg vaginal tablet
Indications -
Cloxacillin Informations générales
SectionAccess group antibiotics- Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid; 250 mg per 5 mL (as sodium salt) powder for oral liquid
- Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 250 mg in vial (as sodium salt) powder for injection
- Oral > Solid > capsule: 500 mg (as sodium salt); 1 g (as sodium salt); 250 mg (as sodium salt)
IndicationsPremier choix
Bacterial infection of joint Osteomyelitis or osteitis Bacterial cellulitis, erysipelas or lymphangitisSecond choix
co-prescrite avec amikacin Sepsis without septic shock -
Clozapine Informations générales
SectionMedicines for psychotic disorders- Oral > Solid: 25 mg; 50 mg; 100 mg; 200 mg
-
Coagulation factor IX Informations générales
SectionBlood coagulation factors- Parenteral > General injections > IV: 500 IU in vial powder for injection; 1000 IU in vial powder for injection
-
Coagulation factor IX complex Informations générales
SectionBlood coagulation factorsIndicationsTherapeutic equivalent to coagulation factor IX pour Coagulation defects, purpura or other haemorrhagic or related conditions Therapeutic equivalent to coagulation factor IX pour Haemophilia B -
Coagulation factor VIII Informations générales
SectionBlood coagulation factors- Parenteral > General injections > IV: 250 IU in vial powder for injection; 500 IU in vial powder for injection; 1000 IU in vial powder for injection
Indications -
Coal tar Informations générales
SectionDermatological medicines > Medicines affecting skin differentiation and proliferation- Local > Topical > Solution: 5%
Indications -
Codeine Informations générales
SectionOpioid analgesics- Oral > Solid: 30 mg tablet (codeine phosphate)
Indications -
Colecalciferol Informations générales
SectionVitamins and minerals- Oral > Liquid: 400 IU per mL
- Oral > Solid: 400 IU; 1000 IU
IndicationsCalcium deficiency Vitamin D deficiency Therapeutic equivalent to ergocalciferol pour Vitamin D deficiency Therapeutic equivalent to ergocalciferol pour Calcium deficiency -
Colistin (injection) Informations générales
SectionReserve group antibiotics- Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium) (equivalent to 34 mg colistin base activity)
-
Compound sodium lactate solution Informations générales
SectionSolutions correcting water, electrolyte and acid-base disturbances > Parenteral- Parenteral > General injections > IV: injectable solution
-
Condoms Informations générales
SectionBarrier methods- -
-
Copper-containing intrauterine device Informations générales
SectionIntrauterine devices- -
-
Cryoprecipitate (not pathogen-reduced) Informations générales
SectionBlood and blood componentsIndicationsTherapeutic equivalent to cryoprecipitate (pathogen-reduced) pour Haemophilia A Therapeutic equivalent to cryoprecipitate (pathogen-reduced) pour Coagulation defects, purpura or other haemorrhagic or related conditions Therapeutic equivalent to cryoprecipitate (pathogen-reduced) pour Von Willebrand disease Therapeutic equivalent to cryoprecipitate (pathogen-reduced) pour Obstetric haemorrhage -
Cryoprecipitate (pathogen-reduced) Informations générales
SectionBlood and blood components- Injection: frozen liquid in bag or lyophilized powder in vial containing:
- > 50 IU Factor VIII
- > 100 IU vWF
- > 140 mg clottable fibrinogen per unit
-
Cyclizine Informations générales
SectionMedicines for other common symptoms in palliative care- Oral > Solid: 50 mg tablet
- Parenteral > General injections > unspecified: 50 mg per mL
Indications -
Cyclopentolate Informations générales
SectionDiagnostic agents > Ophthalmic medicinesIndicationsTherapeutic equivalent to tropicamide pour Cycloplegic drugSectionOphthalmological preparations > MydriaticsIndicationsTherapeutic equivalent to atropine pour Anterior uveitis -
Cyclophosphamide Informations générales
SectionCytotoxic medicines- Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
- Oral > Solid > dosage form: 25 mg; 50 mg
IndicationsOther specified malignant neoplasms of breast Malignant trophoblastic neoplasms of placenta Follicular lymphoma Malignant neoplasms of breast Chronic lymphocytic leukaemia or small lymphocytic lymphoma Rhabdomyosarcoma primary site Hodgkin lymphoma Diffuse large B-cell lymphomas Plasma cell myeloma Other specified gliomas of brain Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis Ewing sarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive -
Cycloserine Informations générales
SectionAntituberculosis medicines- Oral > Solid: 250 mg; 125 mg
Indications -
Cytarabine Informations générales
SectionCytotoxic medicines- Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per mL in vial
Indications -
Dabigatran Informations générales
SectionMedicines affecting coagulation- Oral > Solid: 110 mg; 150 mg
-
Dacarbazine Informations générales
SectionCytotoxic medicines- Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection
Indications -
Daclatasvir Informations générales
SectionMedicines for hepatitis C > Pangenotypic direct-acting antiviral combinations- Oral > Solid > tablet: 30 mg (as hydrochloride); 60 mg (as hydrochloride)
Indications -
Daclatasvir + sofosbuvir Informations générales
SectionMedicines for hepatitis C > Pangenotypic direct-acting antiviral combinations- Oral > Solid > tablet: 60 mg + 400 mg
Indications -
Dactinomycin Informations générales
SectionCytotoxic medicines- Parenteral > General injections > IV: 500 µg in vial powder for injection
-
Dalteparin Informations générales
SectionMedicines affecting coagulationIndicationsTherapeutic equivalent to enoxaparin pour Acute ischaemic heart disease Therapeutic equivalent to enoxaparin pour Venous thromboembolism -
Dapagliflozin Informations générales
SectionOral hypoglycaemic agentsIndicationsTherapeutic equivalent to empagliflozin pour Type 2 diabetes mellitus -
Dapsone Informations générales
SectionAntileprosy medicines- Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet
Indications -
Darbepoetin alfa Informations générales
SectionAntianaemia medicinesIndicationsTherapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease -
Darunavir Informations générales
SectionAntiretrovirals > Protease inhibitors- Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg
-
Dasatinib Informations générales
SectionTargeted therapies- Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet
-
Daunorubicin Informations générales
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)
-
Deferasirox Informations générales
SectionOther medicines for haemoglobinopathies- Oral > Solid > dispersible tablet: 100 mg; 125 mg; 250 mg; 400 mg; 500 mg
- Oral > Solid > tablet: 90 mg; 180 mg; 360 mg
IndicationsOther specified sickle cell disorders or other haemoglobinopathies Thalassaemias Therapeutic equivalent to deferoxamine pour Thalassaemias -
Deferiprone Informations générales
SectionOther medicines for haemoglobinopathiesIndicationsTherapeutic equivalent to deferasirox pour Other specified sickle cell disorders or other haemoglobinopathies Therapeutic equivalent to deferasirox pour Thalassaemias -
Deferoxamine Informations générales
SectionAntidotes and other substances used in poisonings > Specific- Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)
SectionOther medicines for haemoglobinopathies- Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)
-
Delamanid Informations générales
SectionAntituberculosis medicines- Oral > Solid > dispersible tablet: 25 mg
- Oral > Solid > tablet: 50 mg
Indications -
Dengue vaccine Informations générales
SectionRecommendations for some high-risk populations- All vaccines should comply with the WHO requirements for biological substances.
-
Desmopressin Informations générales
SectionMedicines affecting coagulation- Parenteral > General injections > IV: 4 µg per mL in 1 mL ampoule (acetate)
- Local > Nasal > Spray: 10 µg per dose (acetate)
Indications -
Dexamethasone Informations générales
SectionOther medicines administered to the mother- Parenteral > General injections > unspecified: 4 mg per mL (dexamethasone phosphate (as sodium))
SectionHormones and antihormones- Oral > Solid: 4 mg
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosophate salt)
- Oral > Liquid: 2 mg per 5 mL
- Oral > Solid: 2 mg; 4 mg
SectionAntiallergics and medicines used in anaphylaxis- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)
SectionMedicines for other common symptoms in palliative care- Oral > Liquid: 2 mg per 5 mL
- Oral > Solid: 2 mg; 4 mg
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)
IndicationsSectionAntiemetic medicines- Oral > Liquid: 0.5 mg per 5 mL; 2 mg per 5 mL
- Oral > Solid: 0.5 mg; 0.75 mg; 1.5 mg; 4 mg
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)
Indications -
Dextran 70 Informations générales
SectionPlasma substitutes- Parenteral > General injections > IV: 6% injectable solution
Indications -
Diaphragms Informations générales
SectionBarrier methods- -
-
Diazepam Informations générales
SectionAntiseizure medicines- Local > Rectal > Gel: 5 mg per mL in 0.5 mL rectal delivery system; 5 mg per mL in 2 mL rectal delivery system; 5 mg per mL in 4 mL rectal delivery system
- Local > Rectal > Solution: 2 mg per mL in 1.25 mL rectal tube; 2 mg per mL in 2.5 mL rectal tube; 4 mg per mL in 2.5 mL rectal tube
IndicationsSectionMedicines for other common symptoms in palliative care- Oral > Liquid: 2 mg per 5 mL
- Oral > Solid: 5 mg; 10 mg
- Local > Rectal > Gel: 5 mg per mL in 0.5 mL rectal delivery system; 5 mg per mL in 2 mL rectal delivery system; 5 mg per mL in 4 mL rectal delivery system
- Local > Rectal > Solution: 2 mg per mL in 1.25 mL rectal tube; 2 mg per mL in 2.5 mL rectal tube; 4 mg per mL in 2.5 mL rectal tube
- Parenteral > General injections > unspecified: 5 mg per mL
IndicationsSectionMedicines for anxiety disorders- Oral > Solid: 5 mg (scored); 2 mg (scored)
Indications -
Diazoxide Informations générales
SectionMedicines for hypoglycaemia- Oral > Liquid: 50 mg per mL
- Oral > Solid: 50 mg
-
Diethylcarbamazine Informations générales
SectionAntifilarials- Oral > Solid: 50 mg tablet (dihydrogen citrate); 100 mg tablet (dihydrogen citrate)
Indications -
Digoxin Informations générales
SectionAntiarrhythmic medicines- Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule
- Oral > Liquid: 50 µg per mL
- Oral > Solid: 62.5 µg; 250 µg
IndicationsSectionMedicines used in heart failure- Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule; 100 µg per mL in 1 mL ampoule
- Oral > Liquid: 50 µg per mL
- Oral > Solid > tablet: 62.5 µg; 250 µg; 125 µg
Indications -
Dihydroartemisinin + piperaquine phosphate Informations générales
SectionAntimalarial medicines > For curative treatment- Oral > Solid: 40 mg + 320 mg tablet; 20 mg + 160 mg tablet
-
Diloxanide Informations générales
SectionAntiamoebic and antigiardiasis medicines- Oral > Solid: 500 mg (furoate)
Indications -
Dimercaprol Informations générales
SectionAntidotes and other substances used in poisonings > Specific- Parenteral > General injections > IM: 50 mg per mL in 2 mL ampoule
-
Diphtheria antitoxin Informations générales
SectionImmunologicals > Sera, immunoglobulins and monoclonal antibodies- Parenteral > General injections > IM: 10000 IU in vial; 20000 IU in vial
Indications -
Diphtheria vaccine Informations générales
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Docetaxel Informations générales
SectionCytotoxic medicines- Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL
-
Docusate sodium Informations générales
SectionMedicines for other common symptoms in palliative care- Oral > Liquid: 50 mg per 5 mL oral liquid
- Oral > Solid: 100 mg capsule
Indications -
Dolasetron Informations générales
SectionMedicines for other common symptoms in palliative careIndicationsTherapeutic equivalent to ondansetron pour Palliative careSectionAntiemetic medicinesIndicationsTherapeutic equivalent to ondansetron pour Nausea or vomiting -
Dolutegravir Informations générales
SectionAntiretrovirals > Integrase inhibitors- Oral > Solid: 50 mg tablet; 10 mg tablet (dispersible, scored)
-
Dolutegravir + lamivudine + tenofovir Informations générales
SectionFixed-dose combinations of antiretrovirals- Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
-
Dopamine Informations générales
SectionMedicines used in heart failure- Parenteral > General injections > IV: 40 mg per mL in 5 mL vial (hydrochloride)
Indications -
Doxorubicin Informations générales
SectionCytotoxic medicines- Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)
IndicationsMalignant neoplasms of breast Hodgkin lymphoma Diffuse large B-cell lymphomas Plasma cell myeloma Follicular lymphoma Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis Osteosarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Anaplastic large cell lymphoma, ALK-negative Other specified malignant neoplasms of breast Anaplastic large cell lymphoma, ALK-positive Ewing sarcoma of bone and articular cartilage of unspecified sites Kaposi sarcoma of unspecified primary site -
Doxorubicin (as pegylated liposomal) Informations générales
SectionCytotoxic medicines- Parenteral > General injections > IV: 2 mg per mL in 10 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)
Indications -
Doxycycline Informations générales
SectionAntimalarial medicines > For curative treatment- Oral > Solid: 100 mg (hydrochloride or hyclate); 100 mg dispersible tablet (as monohydrate)
IndicationsSectionAntimalarial medicines > For chemoprevention- Oral > Solid: 100 mg (hydrochloride or hyclate)
IndicationsSectionAccess group antibiotics- Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate); 50 mg per 5 mL (calcium)
- Parenteral > General injections > unspecified: 100 mg in vial powder for injection
- Oral > Solid > dispersible tablet: 100 mg (as monohydrate)
- Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate)
- Oral > Solid > dosage form: 100 mg (as hyclate)
-
Edoxaban Informations générales
SectionMedicines affecting coagulationIndicationsTherapeutic equivalent to dabigatran pour Venous thromboembolism Therapeutic equivalent to dabigatran pour Other specified atrial fibrillation -
Efavirenz Informations générales
SectionAntiretrovirals > Non-nucleoside reverse transcriptase inhibitors- Oral > Solid: 600 mg tablet
-
Efavirenz + emtricitabine + tenofovir Informations générales
SectionFixed-dose combinations of antiretrovirals- Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
-
Efavirenz + lamivudine + tenofovir Informations générales
SectionFixed-dose combinations of antiretrovirals- Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)
IndicationsHuman immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Therapeutic equivalent to efavirenz + emtricitabine + tenofovir pour Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified -
Eflornithine Informations générales
SectionMedicines for the treatment of 2nd stage African trypanosomiasis- Parenteral > General injections > IV: 200 mg per mL in 50 mL bottle (hydrochloride)
Indications -
Empagliflozin Informations générales
SectionOral hypoglycaemic agents- Oral > Solid: 10 mg; 25 mg
Indications -
Emtricitabine + tenofovir Informations générales
SectionFixed-dose combinations of antiretrovirals- Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
-
Enalapril Informations générales
SectionAntihypertensive medicines- Oral > Liquid: 1 mg per mL (as hydrogen maleate)
- Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)
IndicationsSectionMedicines used in heart failure- Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)
Indications -
Enoxaparin Informations générales
SectionMedicines affecting coagulation- Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule
Indications -
Entecavir Informations générales
SectionMedicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors- Oral > Liquid: 0.05 mg per mL
- Oral > Solid: 0.5 mg; 1 mg
Indications -
Enzalutamide Informations générales
SectionHormones and antihormonesIndicationsTherapeutic equivalent to abiraterone pour Malignant neoplasms of prostate -
Ephedrine Informations générales
SectionLocal anaesthetics- Parenteral > Locoregional injections > Spinal anaesthesia: 30 mg per mL in 1 mL ampoule (ephedrine hydrochloride)
-
Epinephrine Informations générales
SectionAntiarrhythmic medicines- Parenteral > General injections > IV: 100 µg per mL in 10 mL ampoule (as acid tartrate or hydrochloride)
IndicationsSectionOphthalmological preparations > Mydriatics- Local > Ophthalmological > Solution (eye drops): 2% (as hydrochloride)
IndicationsSectionAntiasthmatic and medicines for chronic obstructive pulmonary disease- Parenteral > General injections > unspecified: 1 mg per mL in ampoule (as hydrochloride or hydrogen tartrate)
IndicationsSectionAntiallergics and medicines used in anaphylaxis- Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (as hydrochloride or hydrogen tartrate)
Indications -
Epoetin alfa Informations générales
SectionAntianaemia medicinesIndicationsTherapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease -
Epoetin beta Informations générales
SectionAntianaemia medicinesIndicationsTherapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease -
Epoetin theta Informations générales
SectionAntianaemia medicinesIndicationsTherapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease -
Equine rabies immunoglobulin Informations générales
SectionImmunologicals > Sera, immunoglobulins and monoclonal antibodies- Parenteral > Locoregional injections > Intradermal: 150 IU per mL in vial; 200 IU per mL in vial; 300 IU per mL in vial; 400 IU per mL in vial
Indications -
Ergocalciferol Informations générales
SectionVitamins and minerals- Oral > Liquid: 250 µg per mL (10 000 IU per mL)
- Oral > Solid: 1.25 mg (50 000 IU)
IndicationsTherapeutic equivalent to colecalciferol pour Calcium deficiency Therapeutic equivalent to colecalciferol pour Vitamin D deficiency Vitamin D deficiency Calcium deficiency -
Ergometrine Informations générales
SectionUterotonics- Parenteral > General injections > unspecified: 200 µg in 1 mL ampoule (hydrogen maleate)
Indications -
Erlotinib Informations générales
SectionTargeted therapies- Oral > Solid: 100 mg; 150 mg
-
Erythromycin Informations générales
SectionOphthalmological preparations > Anti-infective agents- Local > Ophthalmological > Ointment: 0.5%
IndicationsSectionWatch group antibiotics -
Erythropoiesis-stimulating agents Informations générales
SectionAntianaemia medicines- Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe
Indications -
Estradiol cypionate + medroxyprogesterone acetate Informations générales
SectionInjectable hormonal contraceptives- Parenteral > General injections > IM: 5 mg + 25 mg
-
Etanercept Informations générales
SectionImmunomodulators for non-malignant diseaseIndicationsTherapeutic equivalent to adalimumab pour Axial spondyloarthritis Therapeutic equivalent to adalimumab pour Crohn disease site Therapeutic equivalent to adalimumab pour Rheumatoid arthritisSectionMedicines for juvenile joint diseasesIndicationsTherapeutic equivalent to adalimumab pour Juvenile idiopathic arthritis -
Ethambutol Informations générales
SectionAntituberculosis medicines- Oral > Solid > dispersible tablet: 100 mg
- Oral > Solid > tablet: 100 mg (hydrochloride); 400 mg (hydrochloride)
Indications -
Ethambutol + isoniazid + pyrazinamide + rifampicin Informations générales
SectionAntituberculosis medicines- Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet
Indications -
Ethambutol + isoniazid + rifampicin Informations générales
SectionAntituberculosis medicines- Oral > Solid: 275 mg + 75 mg + 150 mg tablet
Indications -
Ethanol Informations générales
SectionAntiseptics- Local > Topical > Solution: 70% (denatured)
Indications -
Ethinylestradiol + etonogestrel Informations générales
SectionIntravaginal contraceptives- Local > Vaginal > vaginal ring: 2.7 mg + 11.7 mg
-
Ethinylestradiol + levonorgestrel Informations générales
SectionOral hormonal contraceptives- Oral > Solid: 30 µg + 150 µg
-
Ethinylestradiol + norethisterone Informations générales
SectionOral hormonal contraceptives- Oral > Solid: 35 µg + 1 mg
-
Ethionamide Informations générales
SectionAntituberculosis medicines- Oral > Solid > dispersible tablet: 125 mg
- Oral > Solid > tablet: 250 mg
-
Ethosuximide Informations générales
SectionAntiseizure medicines- Oral > Liquid: 250 mg per 5 mL
- Oral > Solid: 250 mg
Indications -
Etonogestrel-releasing implant Informations générales
SectionImplantable contraceptives- Implant > Subdermal: 68 mg single rod
-
Etoposide Informations générales
SectionCytotoxic medicines- Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
- Oral > Solid: 100 mg capsule; 50 mg capsule
IndicationsBurkitt lymphoma including Burkitt leukaemia Ewing sarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia Other specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Germ cell tumour of testis Malignant trophoblastic neoplasms of placenta Malignant neoplasms of kidney, except renal pelvis Osteosarcoma of bone and articular cartilage of unspecified sites Hodgkin lymphoma Retinoblastoma Anaplastic large cell lymphoma, ALK-positive Anaplastic large cell lymphoma, ALK-negative -
Everolimus Informations générales
SectionTargeted therapies- Oral > Solid > dispersible tablet: 2 mg; 3 mg; 5 mg
- Oral > Solid > tablet: 2.5 mg; 5 mg; 7.5 mg; 10 mg
Indications -
Fentanyl Informations générales
SectionOpioid analgesics- Local > Topical > Transdermal patch: 12 µg/hour; 25 µg/hour; 50 µg/hour; 75 µg/hour; 100 µg/hour
Indications -
Ferrous salt Informations générales
SectionAntianaemia medicines- Oral > Liquid: 25 mg per mL iron (as sulfate)
- Oral > Solid: 60 mg iron
Indications -
Ferrous salt + folic acid Informations générales
SectionAntianaemia medicines- Oral > Solid > tablet: 60 mg elemental iron + 400 µg tablet; 60 mg elemental iron + 2.8 mg
-
Fexinidazole Informations générales
SectionMedicines for the treatment of 1st stage African trypanosomiasis- Oral > Solid: 600 mg
IndicationsSectionMedicines for the treatment of 2nd stage African trypanosomiasis- Oral > Solid: 600 mg
Indications -
Fexofenadine Informations générales
SectionAntiallergics and medicines used in anaphylaxisIndicationsTherapeutic equivalent to loratadine pour Allergic or hypersensitivity conditions of unspecified type -
Filgrastim Informations générales
SectionImmunomodulators- Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial
Indications -
Fluconazole Informations générales
SectionAntifungal medicines- Parenteral > General injections > IV: 2 mg per mL in vial
- Oral > Liquid: 50 mg per 5 mL; 50 mg per 5 mL powder for oral liquid
- Oral > Solid > capsule: 50 mg
Indications -
Flucytosine Informations générales
SectionAntifungal medicines- Parenteral > General injections > IV: 2.5 g per 250 mL infusion
- Oral > Solid: 250 mg capsule
Indications -
Fludarabine Informations générales
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection
- Oral > Solid: 10 mg tablet (fludarabine phosphate)
-
Fludrocortisone Informations générales
SectionAdrenal hormones and synthetic substitutes- Oral > Solid: 100 µg (acetate)
Indications -
Flunisolide Informations générales
SectionAntiasthmatic and medicines for chronic obstructive pulmonary diseaseIndicationsTherapeutic equivalent to budesonide pour Asthma -
Fluorescein Informations générales
SectionDiagnostic agents > Ophthalmic medicines- Local > Ophthalmological > Solution (eye drops): 1% (sodium salt)
Indications -
Fluoride Informations générales
SectionDental medicines and preparations- Local > Dental > Gel: 2500 to 12500 ppm fluoride (any type)
- Local > Dental > Toothpaste, cream or gel: 1000 to 1500 ppm fluoride (any type)
- Local > Dental > Mouthrinse: 230 to 900 ppm fluoride (any type)
- Local > Dental > Varnish: 22500 ppm fluoride (any type)
Indications -
Fluorouracil Informations générales
SectionDermatological medicines > Medicines affecting skin differentiation and proliferation- Local > Topical > Ointment: 5%
IndicationsSectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg per mL in vial
-
Fluoxetine Informations générales
SectionMedicines for depressive disorders- Oral > Solid: 20 mg (as hydrochloride)
IndicationsSectionMedicines for other common symptoms in palliative care- Oral > Solid: 20 mg (as hydrochloride)
IndicationsSectionMedicines for anxiety disorders- Oral > Solid: 20 mg (as hydrochloride)
SectionMedicines for obsessive compulsive disorders- Oral > Solid: 20 mg (as hydrochloride)
Indications -
Fluphenazine Informations générales
SectionMedicines for psychotic disorders- Parenteral > General injections > IM: 25 mg per mL in ampoule (decanoate); 25 mg per mL in ampoule (enanthate)
-
Flutamide Informations générales
SectionHormones and antihormonesIndicationsTherapeutic equivalent to bicalutamide pour Malignant neoplasms of prostate -
Fluticasone Informations générales
SectionAntiasthmatic and medicines for chronic obstructive pulmonary diseaseIndicationsTherapeutic equivalent to budesonide pour Asthma -
Fluticasone + formoterol Informations générales
SectionAntiasthmatic and medicines for chronic obstructive pulmonary diseaseIndicationsTherapeutic equivalent to budesonide + formoterol pour Asthma -
Fluticasone furoate + vilanterol Informations générales
SectionAntiasthmatic and medicines for chronic obstructive pulmonary diseaseIndicationsTherapeutic equivalent to budesonide + formoterol pour Asthma -
Fluvastatin Informations générales
SectionLipid-lowering agentsIndicationsTherapeutic equivalent to simvastatin pour Mixed hyperlipidaemia Therapeutic equivalent to simvastatin pour Coronary atherosclerosis -
Folic acid Informations générales
SectionAntianaemia medicines- Oral > Solid: 1 mg tablet; 5 mg tablet
- Oral > Solid: 400 µg
-
Fomepizole Informations générales
SectionAntidotes and other substances used in poisonings > Specific- Parenteral > General injections > IV: 5 mg per mL in 20 mL ampoule (sulfate); 1 g per mL in 1.5 mL ampoule (base)
-
Fosfomycin (injection) Informations générales
SectionReserve group antibiotics- Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection
-
Fresh-frozen plasma Informations générales
SectionBlood and blood components- Parenteral > General injections > IV:
Indications -
Furosemide Informations générales
SectionMedicines used in heart failure- Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
- Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL
- Oral > Solid > tablet: 40 mg; 20 mg
IndicationsSectionDiuretics- Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
- Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL
- Oral > Solid > tablet: 40 mg; 20 mg
Indications -
Gefitinib Informations générales
SectionTargeted therapiesIndicationsTherapeutic equivalent to erlotinib pour Other specified malignant neoplasms of bronchus or lung -
Gemcitabine Informations générales
SectionCytotoxic medicines- Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection
-
Gentamicin Informations générales
SectionAccess group antibiotics- Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)
IndicationsPremier choix
Neonatal meningitis co-prescrite avec amoxicillin Sepsis without septic shock co-prescrite avec amoxicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec ampicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec ampicillin Sepsis without septic shock co-prescrite avec ampicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec ampicillin Peritoneal abscess (severe) co-prescrite avec ampicillin Peritonitis (mild-moderate) co-prescrite avec ampicillin Peritonitis (severe) co-prescrite avec ampicillin Peritoneal abscess (mild-moderate) co-prescrite avec benzylpenicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec benzylpenicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec benzylpenicillin Sepsis without septic shockSectionOphthalmological preparations > Anti-infective agents- Local > Ophthalmological > Solution (eye drops): 0.3% (gentamicin sulfate)
Indications -
Glass ionomer cement Informations générales
SectionDental medicines and preparations- Local > Dental > Powder + liquid: Single-use capsules: 0.4 g powder + 0.09 mL liquid; Multi-use bottle: powder + liquid
Indications -
Glatiramer acetate Informations générales
SectionMedicines for multiple sclerosis- Parenteral > General injections > SC: 20 mg per mL in pre-filled syringe; 40 mg per mL in pre-filled syringe
Indications -
Glecaprevir + pibrentasvir Informations générales
SectionMedicines for hepatitis C > Pangenotypic direct-acting antiviral combinations- Oral > Solid: 50 mg + 20 mg granules
- Oral > Solid > tablet: 100 mg + 40 mg
Indications -
Gliclazide Informations générales
SectionOral hypoglycaemic agents- Oral > Solid: 30 mg controlled-release; 60 mg controlled-release; 80 mg controlled-release
Indications -
Glucagon Informations générales
SectionMedicines for hypoglycaemia- Parenteral > General injections > unspecified: 1 mg per mL
Indications -
Glucose Informations générales
SectionSolutions correcting water, electrolyte and acid-base disturbances > Parenteral- Parenteral > General injections > IV: 5% isotonic; 10% hypertonic
- Parenteral > General injections > IV: 50% hypertonic
-
Glucose + sodium chloride Informations générales
SectionSolutions correcting water, electrolyte and acid-base disturbances > Parenteral- Parenteral > General injections > IV: 4% + 0.18% (equivalent to Na+ 30 mmol/L and Cl- 30 mmol/L; 5% + 0.9% (equivalent to Na+ 150 mmol/L and Cl- 150 mmol/L); 5% + 0.45% (equivalent to Na+ 75 mmol/L and Cl- 75 mmol/L)
-
Glutaral Informations générales
SectionDisinfectants- Local > Topical > Solution: 2%
Indications -
Glyceryl trinitrate Informations générales
SectionAntianginal medicines- Oral > Solid: 500 µg sublingual tablet
Indications -
Glycopyrronium Informations générales
SectionAntiasthmatic and medicines for chronic obstructive pulmonary diseaseIndicationsTherapeutic equivalent to tiotropium bromide pour Chronic obstructive pulmonary disease -
Golimumab Informations générales
SectionImmunomodulators for non-malignant diseaseIndicationsTherapeutic equivalent to adalimumab pour Axial spondyloarthritis Therapeutic equivalent to adalimumab pour Crohn disease site Therapeutic equivalent to adalimumab pour Rheumatoid arthritisSectionMedicines for juvenile joint diseasesIndicationsTherapeutic equivalent to adalimumab pour Juvenile idiopathic arthritis -
Goserelin Informations générales
SectionHormones and antihormonesIndicationsTherapeutic equivalent to leuprorelin pour Malignant neoplasms of breast Therapeutic equivalent to leuprorelin pour Malignant neoplasms of prostate -
Granisetron Informations générales
SectionMedicines for other common symptoms in palliative careIndicationsTherapeutic equivalent to ondansetron pour Palliative careSectionAntiemetic medicinesIndicationsTherapeutic equivalent to ondansetron pour Nausea or vomiting -
Griseofulvin Informations générales
SectionAntifungal medicines- Oral > Liquid: 125 mg per 5 mL
- Oral > Solid: 125 mg; 250 mg
Indications -
Haemophilus influenzae type b vaccine Informations générales
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
-
Haloperidol Informations générales
SectionMedicines for other common symptoms in palliative care- Oral > Liquid: 2 mg per mL
- Oral > Solid: 0.5 mg; 2 mg; 5 mg
- Parenteral > General injections > unspecified: 5 mg per mL in 1-mL ampoule
IndicationsSectionMedicines for psychotic disorders- Parenteral > General injections > IM: 5 mg per mL in ampoule
- Oral > Solid: 2 mg; 5 mg
-
Haloperidol decanoate Informations générales
SectionMedicines for psychotic disordersIndicationsTherapeutic equivalent to fluphenazine pour Schizophrenia or other primary psychotic disorders -
Halothane Informations générales
SectionGeneral anaesthetics and oxygen > Inhalational medicines- Respiratory > Inhalation > liquid:
Indications -
Heparin sodium Informations générales
SectionMedicines affecting coagulation- Parenteral > General injections > IV: 1000 IU per mL in 5 mL ampoule; 20000 IU per mL in 5 mL ampoule; 5000 IU per mL in 5 mL ampoule
-
Hepatitis A vaccine Informations générales
SectionRecommendations for some high-risk populations- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Hepatitis B vaccine Informations générales
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Homatropine Informations générales
SectionOphthalmological preparations > MydriaticsIndicationsTherapeutic equivalent to atropine pour Anterior uveitis -
Human papilloma virus (HPV) vaccine Informations générales
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
-
Hydralazine Informations générales
SectionAntihypertensive medicines- Parenteral > General injections > IV: 20 mg in ampoule powder for injection (hydrochloride)
- Oral > Solid: 50 mg (hydrochloride); 25 mg (hydrochloride)
Indications -
Hydrochlorothiazide Informations générales
SectionAntihypertensive medicines- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid: 25 mg; 12.5 mg
IndicationsSectionMedicines used in heart failure- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid: 25 mg
IndicationsSectionDiuretics- Oral > Solid: 25 mg
Indications -
Hydrocortisone Informations générales
SectionHormones and antihormones- Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)
SectionAdrenal hormones and synthetic substitutes- Oral > Solid: 5 mg; 10 mg; 20 mg
IndicationsSectionAntiallergics and medicines used in anaphylaxis- Parenteral > General injections > unspecified: 100 mg in vial powder for injection (as sodium succinate)
IndicationsSectionAnti-inflammatory medicines- Local > Rectal > Suppository: 25 mg (acetate)
- Local > Rectal > Retention enema: 100 mg per 60 mL
IndicationsSectionDermatological medicines > Anti-inflammatory and antipruritic medicines- Local > Topical > Cream: 1% (acetate)
- Local > Topical > Ointment: 1% (acetate)
-
Hydromorphone Informations générales
-
Hydroxocobalamin Informations générales
SectionAntianaemia medicines- Parenteral > General injections > IM: 1 mg per mL in 1 mL ampoule (as acetate); 1 mg per mL in 1 mL ampoule (as hydrochloride); 1 mg per mL in 1 mL ampoule (as sulfate)
-
Hydroxycarbamide (hydroxyurea) Informations générales
SectionCytotoxic medicines- Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg
SectionOther medicines for haemoglobinopathies- Oral > Solid > dosage form: 200 mg; 500 mg; 1 g; 100 mg
-
Hydroxychloroquine Informations générales
SectionDisease-modifying anti-rheumatic drugs (DMARDs)- Oral > Solid: 200 mg (as sulfate)
-
Hyoscine butylbromide Informations générales
SectionMedicines for other common symptoms in palliative care- Parenteral > General injections > unspecified: 20 mg per mL injection
Indications -
Hyoscine hydrobromide Informations générales
SectionMedicines for other common symptoms in palliative care- Local > Topical > Transdermal patch: 1 mg per 72 hours transdermal patch
- Parenteral > General injections > unspecified: 400 µg per mL injection; 600 µg per mL injection
Indications -
Ibrutinib Informations générales
SectionTargeted therapies- Oral > Solid: 140 mg
-
Ibuprofen Informations générales
SectionMedicines administered to the neonate [c]- Parenteral > General injections > IV: 5 mg per mL
IndicationsSectionNon-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)- Oral > Liquid: 200 mg per 5 mL; 100 mg per 5 mL
- Oral > Solid > tablet: 200 mg; 400 mg; 600 mg
IndicationsSectionAntimigraine medicines > For treatment of acute attack- Oral > Liquid: 100 mg per 5 mL; 200 mg per 5 mL
- Oral > Solid > tablet: 200 mg; 400 mg
Indications -
Ifosfamide Informations générales
SectionCytotoxic medicines- Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
IndicationsOther specified malignant neoplasms of the ovary Germ cell tumour of testis Ewing sarcoma of bone and articular cartilage of unspecified sites Osteosarcoma of bone and articular cartilage of unspecified sites Rhabdomyosarcoma primary site Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive -
Imatinib Informations générales
SectionTargeted therapies- Oral > Solid: 100 mg; 400 mg
-
Imipenem + cilastatin Informations générales
SectionAntituberculosis medicinesIndicationsTherapeutic equivalent to meropenem pour Multi-drug resistant Mycobacterium tuberculosisSectionWatch group antibioticsIndicationsSecond choix
Therapeutic equivalent to meropenem pour Neutropenia (high-risk) Therapeutic equivalent to meropenem pour Peritoneal abscess (severe) Therapeutic equivalent to meropenem pour Peritonitis (severe) -
Indapamide Informations générales
SectionAntihypertensive medicinesIndicationsTherapeutic equivalent to hydrochlorothiazide pour Essential hypertensionSectionMedicines used in heart failureIndicationsTherapeutic equivalent to hydrochlorothiazide pour Heart failure -
Indometacin Informations générales
SectionMedicines administered to the neonate [c]IndicationsTherapeutic equivalent to ibuprofen pour Patent arterial duct -
Infliximab Informations générales
SectionImmunomodulators for non-malignant diseaseIndicationsTherapeutic equivalent to adalimumab pour Axial spondyloarthritis Therapeutic equivalent to adalimumab pour Crohn disease site Therapeutic equivalent to adalimumab pour Rheumatoid arthritisSectionMedicines for juvenile joint diseasesIndicationsTherapeutic equivalent to adalimumab pour Juvenile idiopathic arthritis -
Influenza vaccine (seasonal) Informations générales
SectionRecommendations for immunization programmes with certain characteristics- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Insulin Informations générales
SectionInsulins- Parenteral > General injections > SC: 40 IU per mL in 10 mL vial (soluble); 100 IU per mL in 10 mL vial (soluble); 100 IU per mL in 3 mL cartridge (soluble); 100 IU per mL in 3 mL pre-filled pen (soluble)
Indications -
Insulin degludec Informations générales
SectionInsulinsIndicationsTherapeutic equivalent to long-acting insulin analogues pour Type 1 diabetes mellitus Therapeutic equivalent to long-acting insulin analogues pour Type 2 diabetes mellitus -
Insulin detemir Informations générales
SectionInsulinsIndicationsTherapeutic equivalent to long-acting insulin analogues pour Type 1 diabetes mellitus Therapeutic equivalent to long-acting insulin analogues pour Type 2 diabetes mellitus -
Insulin glargine Informations générales
SectionInsulinsIndicationsTherapeutic equivalent to long-acting insulin analogues pour Type 1 diabetes mellitus Therapeutic equivalent to long-acting insulin analogues pour Type 2 diabetes mellitus -
Intermediate-acting insulin Informations générales
SectionInsulins- Parenteral > General injections > SC: 40 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL cartridge as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL pre-filled pen as compound insulin zinc suspension or isophane insulin
Indications -
Intraperitoneal dialysis solution Informations générales
SectionPeritoneal dialysis solution- parenteral solution
Indications -
Iodine Informations générales
SectionVitamins and minerals- Parenteral > General injections > IM: 0.5 mL (240 mg iodine) iodized oil in ampoule; 1 mL (480 mg iodine) iodized oil in ampoule
- Oral > Liquid: 1 mL (480 mg iodine) iodized oil in ampoule; 0.5 mL (240 mg iodine) iodized oil in ampoule; 0.57 mL (308 mg iodine) iodized oil in dispenser bottle
- Oral > Solid: 190 mg
IndicationsSectionAntisepticsIndicationsTherapeutic equivalent to povidone iodine pour Povidone iodine -
Iohexol Informations générales
SectionDiagnostic agents > Radiocontrast media- Parenteral > General injections > unspecified: 140 to 350 mg iodine per mL in 5 mL ampoule; 140 to 350 mg iodine per mL in 10 mL ampoule; 140 to 350 mg iodine per mL in 20 mL ampoule
Indications -
Ipratropium bromide Informations générales
SectionAntiasthmatic and medicines for chronic obstructive pulmonary disease- Respiratory > Inhalation > aerosol: 20 µg per dose
Indications -
Irinotecan Informations générales
SectionCytotoxic medicines- Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial
-
Isoflurane Informations générales
SectionGeneral anaesthetics and oxygen > Inhalational medicines- Respiratory > Inhalation > liquid:
Indications -
Isoniazid Informations générales
SectionAntituberculosis medicines- Oral > Solid > dispersible tablet: 100 mg
- Oral > Solid > tablet: 100 mg; 300 mg
Indications -
Isoniazid + pyrazinamide + rifampicin Informations générales
SectionAntituberculosis medicines- Oral > Solid > dispersible tablet: 50 mg + 150 mg + 75 mg
Indications -
Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim Informations générales
SectionMedicines for prevention of HIV-related opportunistic infections- Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)
Indications -
Isoniazid + rifampicin Informations générales
SectionAntituberculosis medicines- Oral > Solid > dispersible tablet: 50 mg + 75 mg
- Oral > Solid > tablet: 75 mg + 150 mg; 150 mg + 300 mg
Indications -
Isoniazid + rifapentine Informations générales
SectionAntituberculosis medicines- Oral > Solid: 300 mg + 300 mg tablet (scored)
Indications -
Isosorbide dinitrate Informations générales
SectionAntianginal medicines- Oral > Solid: 5 mg sublingual tablet
Indications -
Itraconazole Informations générales
SectionAntifungal medicines- Oral > Liquid: 10 mg per mL
- Oral > Solid: 100 mg
-
Ivermectin Informations générales
SectionIntestinal anthelminthics- Oral > Solid > tablet: 3 mg
SectionAntifilarials- Oral > Solid > tablet: 3 mg
IndicationsSectionMedicines for ectoparasitic infections- Oral > Solid > tablet: 3 mg
Indications -
Kanamycin Informations générales
SectionOphthalmological preparations > Anti-infective agentsIndicationsTherapeutic equivalent to gentamicin pour Other specified conjunctivitis Therapeutic equivalent to gentamicin pour Infectious blepharitis -
Ketamine Informations générales
SectionGeneral anaesthetics and oxygen > Injectable medicines- Parenteral > General injections > unspecified: 50 mg per mL in 10 mL vial (as hydrochloride)
Indications -
Lactulose Informations générales
SectionMedicines for other common symptoms in palliative care- Oral > Liquid: 3.1 to 3.7 g per 5 mL oral liquid
Indications -
Lamivudine Informations générales
SectionAntiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid: 150 mg tablet
-
Lamivudine + tenofovir Informations générales
SectionFixed-dose combinations of antiretroviralsIndicationsTherapeutic equivalent to emtricitabine + tenofovir pour Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Therapeutic equivalent to emtricitabine + tenofovir pour Contact with or exposure to human immunodeficiency virus -
Lamivudine + zidovudine Informations générales
SectionFixed-dose combinations of antiretrovirals- Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet
-
Lamotrigine Informations générales
SectionAntiseizure medicines- Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet; 200 mg tablet; 2 mg tablet (chewable, dispersible); 5 mg tablet (chewable, dispersible); 25 mg tablet (chewable, dispersible); 50 mg tablet (chewable, dispersible); 100 mg tablet (chewable, dispersible); 200 mg tablet (chewable, dispersible)
Indications -
Latanoprost Informations générales
SectionOphthalmological preparations > Miotics and antiglaucoma medicines- Local > Ophthalmological > Solution (eye drops): 50 µg per mL eye drops
Indications -
Ledipasvir + sofosbuvir Informations générales
SectionMedicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations- Oral > Solid: 90 mg + 400 mg tablet
Indications -
Lenalidomide Informations générales
SectionImmunomodulators- Oral > Solid: 25 mg
Indications -
Letrozole Informations générales
SectionOvulation inducers- Oral > Solid > dosage form: 2.5 mg
-
Leuprorelin Informations générales
SectionHormones and antihormones- Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe
-
Levamisole Informations générales
SectionIntestinal anthelminthics- Oral > Solid > tablet: 50 mg (as hydrochloride); 150 mg (as hydrochloride)
Indications -
Levetiracetam Informations générales
SectionAntiseizure medicines- Oral > Liquid: 100 mg per mL
- Oral > Solid > tablet: 250 mg; 500 mg; 750 mg; 1000 mg
- Parenteral > General injections > IV: 500 mg per 5 mL in 5 mL vial; 5 mg per mL in 100 mL bag; 10 mg per mL in 100 mL bag; 15 mg per mL in 100 mL bag
Indications -
Levodopa + benserazide Informations générales
SectionMedicines for parkinsonismIndicationsTherapeutic equivalent to levodopa + carbidopa pour Parkinson disease -
Levodopa + carbidopa Informations générales
SectionMedicines for parkinsonism- Oral > Solid: 100 mg + 10 mg tablet; 250 mg + 25 mg tablet; 100 mg + 25 mg tablet
Indications -
Levofloxacin Informations générales
SectionAntituberculosis medicines- Oral > Solid > dispersible tablet: 100 mg
- Oral > Solid > tablet: 250 mg; 500 mg; 750 mg
Indications -
Levonorgestrel Informations générales
SectionOral hormonal contraceptives- Oral > Solid: 750 µg [2]; 1.5 mg [1]
- Oral > Solid: 30 µg
SectionIntrauterine devices- Intrauterine system with reservoir containing 52 mg of levonorgestrel.
-
Levonorgestrel-releasing implant Informations générales
SectionImplantable contraceptives- Implant > Subdermal: 75 mg per rod (two-rods)
-
Levothyroxine Informations générales
SectionThyroid hormones and antithyroid medicines- Oral > Solid: 50 µg (sodium salt); 100 µg (sodium salt); 25 µg (sodium salt)
Indications -
Lidocaine Informations générales
SectionAntiarrhythmic medicines- Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule (hydrochloride)
IndicationsSectionLocal anaesthetics- Parenteral > Locoregional injections > Spinal anaesthesia: 5% in 2 mL ampoule (hydrochloride) + 7.5% glucose solution
- Parenteral > Locoregional injections > Other: 1% in vial (hydrochloride); 2% in vial (hydrochloride)
- Local > Topical > unspecified: 2 to 4% (hydrochloride)
Indications -
Lidocaine + epinephrine Informations générales
SectionLocal anaesthetics- Parenteral > Locoregional injections > Other: 1% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine in vial; 2% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine in vial
- Local > Dental > Cartridge: 2% (lidocaine hydrochloride) + 1:80 000 epinephrine
Indications -
Linezolid Informations générales
SectionReserve group antibiotics- Parenteral > General injections > IV: 2 mg per mL in 300 mL bag
- Oral > Liquid: 100 mg per 5 mL powder for oral liquid
- Oral > Solid > dispersible tablet: 150 mg
- Oral > Solid > tablet: 600 mg
SectionAntituberculosis medicines- Oral > Solid > dispersible tablet: 150 mg
- Oral > Solid > tablet: 600 mg
Indications -
Lisinopril + amlodipine Informations générales
SectionAntihypertensive medicines- Oral > Solid: 10 mg + 5 mg; 20 mg + 5 mg; 20 mg + 10 mg
Indications -
Lisinopril + hydrochlorothiazide Informations générales
SectionAntihypertensive medicines- Oral > Solid: 10 mg + 12.5 mg; 20 mg + 12.5 mg; 20 mg + 25 mg
Indications -
Lithium carbonate Informations générales
SectionMedicines for bipolar disorders- Oral > Solid: 300 mg
Indications -
Long-acting insulin analogues Informations générales
SectionInsulins- Parenteral > General injections > SC: 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen
Indications -
Loperamide Informations générales
SectionMedicines for other common symptoms in palliative care- Oral > Solid > dosage form: 2 mg
Indications -
Lopinavir + ritonavir Informations générales
SectionAntiretrovirals > Protease inhibitors- Oral > Solid > tablet: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable)
- Oral > Solid > dosage form: 40 mg + 10 mg
-
Loratadine Informations générales
SectionAntiallergics and medicines used in anaphylaxis- Oral > Liquid: 1 mg per mL
- Oral > Solid: 10 mg
-
Lorazepam Informations générales
SectionAntiseizure medicines- Parenteral > General injections > IV: 2 mg per mL in 1 mL ampoule; 4 mg per mL in 1 mL ampoule
Indications -
Losartan Informations générales
SectionAntihypertensive medicines- Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet
IndicationsSectionMedicines used in heart failure- Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet
Indications -
Lovastatin Informations générales
SectionLipid-lowering agentsIndicationsTherapeutic equivalent to simvastatin pour Mixed hyperlipidaemia Therapeutic equivalent to simvastatin pour Coronary atherosclerosis -
Lugol's solution Informations générales
SectionThyroid hormones and antithyroid medicines- Oral > Liquid: 13% w/v (about 130 mg/mL total iodine)
Indications -
Magnesium sulfate Informations générales
SectionAntiseizure medicines- Parenteral > General injections > IV: 500 mg per mL in 2 mL ampoule (equivalent to 1 g in 2 mL; 50% weight/volume)
- Parenteral > General injections > IM: 500 mg per mL in 10 mL ampoule (equivalent to 5 g in 10 mL; 50% weight/volume)
Indications -
Mannitol Informations générales
SectionDiuretics- Parenteral > General injections > IV: 10% solution; 20% solution
Indications -
Measles vaccine Informations générales
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Mebendazole Informations générales
SectionIntestinal anthelminthics- Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)
IndicationsSectionCysticidal medicines- Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)
Indications -
Medroxyprogesterone acetate Informations générales
SectionInjectable hormonal contraceptives- Parenteral > General injections > IM: 150 mg per mL in 1 mL vial
- Parenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system
SectionProgestogens- Oral > Solid: 5 mg
Indications -
Mefloquine Informations générales
SectionAntimalarial medicines > For curative treatment- Oral > Solid: 250 mg tablet (hydrochloride)
SectionAntimalarial medicines > For chemoprevention- Oral > Solid: 250 mg tablet (hydrochloride)
Indications -
Meglumine antimoniate Informations générales
SectionAntileishmaniasis medicines- Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule
-
Meglumine iotroxate Informations générales
SectionDiagnostic agents > Radiocontrast media- Parenteral > General injections > IV: 5 to 8 g iodine (as meglumine) in 100 to 250 mL
Indications -
Melarsoprol Informations générales
SectionMedicines for the treatment of 2nd stage African trypanosomiasis- Parenteral > General injections > IV: 3.6% in 5 mL ampoule solution (180 mg of active compound)
Indications -
Melphalan Informations générales
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial powder for injection
- Oral > Solid: 2 mg
Indications -
Meningococcal meningitis vaccine Informations générales
SectionRecommendations for some high-risk populations- All vaccines should comply with the WHO requirements for biological substances.
-
Mercaptopurine Informations générales
SectionCytotoxic medicines- Oral > Liquid: 20 mg per mL
- Oral > Solid: 50 mg tablet
-
Meropenem Informations générales
SectionWatch group antibiotics- Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
IndicationsSectionAntituberculosis medicines- Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
Indications -
Meropenem + vaborbactam Informations générales
SectionReserve group antibiotics- Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection
-
Mesalazine Informations générales
SectionAnti-inflammatory medicinesIndicationsTherapeutic equivalent to sulfasalazine pour Crohn disease site Therapeutic equivalent to sulfasalazine pour Ulcerative colitis -
Mesna Informations générales
SectionSupportive medicines- Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule
- Oral > Solid: 400 mg; 600 mg
IndicationsOsteosarcoma of bone and articular cartilage of other specified sites Other specified malignant neoplasms of the ovary Germ cell tumour of testis Ewing sarcoma of bone and articular cartilage of unspecified sites Rhabdomyosarcoma primary site Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis -
Metformin Informations générales
SectionOral hypoglycaemic agents- Oral > Solid: 500 mg (hydrochloride)
Indications -
Methadone Informations générales
SectionMedicines for opioid use disorders- Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)
IndicationsSectionOpioid analgesics- Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)
- Oral > Solid: 5 mg (methadone hydrochloride); 10 mg (methadone hydrochloride)
Indications -
Methimazole Informations générales
SectionThyroid hormones and antithyroid medicines- Oral > Solid: 5 mg; 10 mg; 20 mg
Indications -
Methotrexate Informations générales
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection
- Oral > Solid: 2.5 mg (as sodium salt)
IndicationsLymphoid leukaemia, not elsewhere classified Acute myeloid leukaemia with recurrent genetic abnormalities Malignant trophoblastic neoplasms of placenta Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of breast Osteosarcoma of bone and articular cartilage of unspecified sites Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosisSectionDermatological medicines > Medicines affecting skin differentiation and proliferation- Oral > Solid > tablet: 2.5 mg (as sodium salt); 10 mg (as sodium salt)
IndicationsSectionDisease-modifying anti-rheumatic drugs (DMARDs)- Oral > Solid > tablet: 2.5 mg (as sodium salt)
IndicationsSectionMedicines for juvenile joint diseases- Oral > Solid > tablet: 2.5 mg (as sodium salt)
Indications -
Methoxy polyethylene glycol-epoetin beta Informations générales
SectionAntianaemia medicinesIndicationsTherapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease -
Methyldopa Informations générales
SectionAntihypertensive medicines- Oral > Solid: 250 mg
Indications -
Methylergometrine Informations générales
SectionUterotonicsIndicationsTherapeutic equivalent to ergometrine pour Postpartum haemorrhage -
Methylprednisolone Informations générales
SectionHormones and antihormones- Parenteral > General injections > IV: 40 mg per mL in 1 mL single-dose vial (as sodium succinate); 40 mg per mL in 5 mL multi-dose vial (as sodium succinate); 80 mg per mL in 1 mL single-dose vial (as sodium succinate)
-
Methylthioninium chloride Informations générales
SectionAntidotes and other substances used in poisonings > Specific- Parenteral > General injections > IV: 10 mg per mL in 10 mL ampoule
Indications -
Metoclopramide Informations générales
SectionMedicines for other common symptoms in palliative care- Oral > Liquid: 5 mg per 5 mL
- Oral > Solid: 10 mg (hydrochloride)
- Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)
IndicationsSectionAntiemetic medicines- Oral > Liquid: 5 mg per 5 mL
- Oral > Solid: 10 mg (hydrochloride)
- Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)
Indications -
Metoprolol Informations générales
SectionAntianginal medicinesIndicationsTherapeutic equivalent to bisoprolol pour Angina pectorisSectionMedicines used in heart failureIndicationsTherapeutic equivalent to bisoprolol pour Heart failureSectionAntihypertensive medicinesIndicationsTherapeutic equivalent to bisoprolol pour Essential hypertensionSectionAntiarrhythmic medicinesIndicationsTherapeutic equivalent to bisoprolol pour Cardiac arrhythmia -
Metronidazole Informations générales
SectionAntiamoebic and antigiardiasis medicines- Oral > Liquid: 200 mg per 5 mL (as benzoate)
- Parenteral > General injections > unspecified: 500 mg in 100 mL vial
- Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg
IndicationsSectionAccess group antibiotics- Oral > Liquid: 200 mg per 5 mL (as benzoate)
- Local > Rectal > Suppository: 500 mg; 1 g
- Parenteral > General injections > unspecified: 500 mg per 100 mL in vial
- Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg
IndicationsPremier choix
Intestinal infections due to Clostridioides difficile Trichomoniasis co-prescrite avec cefazolin Other specified prophylactic measures co-prescrite avec cefotaxime Peritonitis (severe) co-prescrite avec cefotaxime Peritonitis (mild-moderate) co-prescrite avec cefotaxime Peritoneal abscess (mild-moderate) co-prescrite avec cefotaxime Peritoneal abscess (severe) co-prescrite avec ceftriaxone Necrotising fasciitis co-prescrite avec ceftriaxone Peritonitis (severe) co-prescrite avec ceftriaxone Peritoneal abscess (mild-moderate) co-prescrite avec ceftriaxone Peritoneal abscess (severe) co-prescrite avec ceftriaxone Peritonitis (mild-moderate)Second choix
co-prescrite avec ciprofloxacin Peritonitis (mild-moderate) co-prescrite avec ciprofloxacin Peritoneal abscess (mild-moderate) -
Micafungin Informations générales
SectionAntifungal medicines- Parenteral > General injections > IV: 50 mg in vial (as sodium) powder for injection; 100 mg in vial (as sodium) powder for injection
Indications -
Miconazole Informations générales
SectionDermatological medicines > Antifungal medicines- Local > Topical > Cream: 2% (nitrate)
- Local > Topical > Ointment: 2% (nitrate)
Indications -
Midazolam Informations générales
SectionAntiseizure medicines- Parenteral > General injections > unspecified: 1 mg per mL in 5 mL vial (for buccal administration); 5 mg per mL in 1 mL vial (for buccal administration); 5 mg per mL in 3 mL vial (for buccal administration)
- Local > Buccal > Solution: 5 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 2 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.25 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.75 mL pre-filled syringe; 10 mg per mL in 1 mL pre-filled syringe (for oromucosal administration)
IndicationsSectionPreoperative medication and sedation for short-term procedures- Parenteral > General injections > IV: 1 mg per mL
- Oral > Liquid: 2 mg per mL
- Oral > Solid > dosage form: 15 mg; 7.5 mg
IndicationsSectionMedicines for other common symptoms in palliative care- Oral > Liquid: 2 mg per mL
- Parenteral > General injections > unspecified: 1 mg per mL; 5 mg per mL
- Oral > Solid > dosage form: 7.5 mg; 15 mg
Indications -
Mifepristone - misoprostol Informations générales
SectionUterotonics- Oral > Solid: 200 mg + 200 µg; 200 mg [1] + 200 µg [4] in co-package
-
Miltefosine Informations générales
SectionAntileishmaniasis medicines- Oral > Solid: 10 mg; 50 mg
-
Misoprostol Informations générales
SectionUterotonics- Oral > Solid: 200 µg
- Local > Vaginal > tablet: 25 µg
-
Mometasone Informations générales
SectionAntiasthmatic and medicines for chronic obstructive pulmonary diseaseIndicationsTherapeutic equivalent to budesonide pour Asthma -
Mometasone + formoterol Informations générales
SectionAntiasthmatic and medicines for chronic obstructive pulmonary diseaseIndicationsTherapeutic equivalent to budesonide + formoterol pour Asthma -
Morphine Informations générales
SectionOpioid analgesics- Oral > Liquid: 10 mg per 5 mL (morphine hydrochloride or morphine sulfate)
- Oral > Solid: 10 mg immediate release (morphine sulfate); 10 to 200 mg slow release (morphine hydrochloride or morphine sulfate)
- Oral > Other: 20 to 200 mg slow release granules to mix with water (morphine sulfate)
- Parenteral > General injections > unspecified: 10 mg in 1 mL ampoule (morphine hydrochloride or morphine sulfate)
IndicationsSectionPreoperative medication and sedation for short-term procedures- Parenteral > General injections > IV: 10 mg in 1 mL ampoule (morphine hydrochloride or morphine sulfate)
-
Moxifloxacin Informations générales
SectionAntituberculosis medicines- Oral > Solid > dispersible tablet: 100 mg
- Oral > Solid > tablet: 400 mg
-
Multiple micronutrient powder Informations générales
SectionVitamins and minerals- Sachets containing:
- - iron (elemental) 12.5 mg (as coated ferrous fumarate)
- - zinc (elemental) 5 mg
- - vitamin A 300 micrograms
- - with or without other micronutrients at recommended daily values
Indications -
Multiple micronutrient supplement Informations générales
SectionOther medicines administered to the mother- Tablet containing:
- Vit A: 800 mcg retinol activity equivalent
- Vit C: 70 mg
- Vit D: 5 mcg (200 IU)
- Vit E: 10 mg alpha tocopherol equivalent
- Vit B1: 1.4 mg
- Vit B2: 1.4 mg
- Vit B3: 18 mg niacin equivalent
- Vit B6: 1.9 mg
- Folic acid: 400 mcg
- Vit B12: 2.6 mcg
- Iron: 30 mg
- Iodine: 150 mcg
- Zinc: 15 mg
- Selenium: 65 mcg
- Copper: 2 mg
-
Mumps vaccine Informations générales
SectionRecommendations for immunization programmes with certain characteristics- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Mupirocin Informations générales
SectionDermatological medicines > Anti-infective medicines- Local > Topical > Cream: 2% (as mupirocin calcium)
- Local > Topical > Ointment: 2%
Indications -
Nadroparin Informations générales
SectionMedicines affecting coagulationIndicationsTherapeutic equivalent to enoxaparin pour Acute ischaemic heart disease Therapeutic equivalent to enoxaparin pour Venous thromboembolism -
Naloxone Informations générales
SectionAntidotes and other substances used in poisonings > Specific- Parenteral > General injections > unspecified: 400 µg per 1 mL in ampoule (naloxone hydrochloride)
-
Naltrexone Informations générales
SectionMedicines for alcohol use disorders- Parenteral > General injections > IM: 380 mg in vial (extended-release)
- Oral > Solid > tablet: 50 mg
Indications -
Natamycin Informations générales
SectionOphthalmological preparations > Anti-infective agents- Local > Ophthalmological > Suspension: 5% eye drops
Indications -
Neostigmine Informations générales
SectionMuscle relaxants (peripherally-acting) and cholinesterase inhibitors- Oral > Solid: 15 mg (neostigmine bromide)
- Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)
Indications -
Netilmicin Informations générales
SectionOphthalmological preparations > Anti-infective agentsIndicationsTherapeutic equivalent to gentamicin pour Other specified conjunctivitis Therapeutic equivalent to gentamicin pour Infectious blepharitis -
Nevirapine Informations générales
SectionAntiretrovirals > Non-nucleoside reverse transcriptase inhibitors- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid > dispersible tablet: 50 mg
- Oral > Solid > tablet: 200 mg
-
Niclosamide Informations générales
SectionIntestinal anthelminthics- Oral > Solid: 500 mg tablet (chewable)
-
Nicotinamide Informations générales
SectionVitamins and minerals- Oral > Solid: 50 mg
Indications -
Nicotine replacement therapy Informations générales
SectionMedicines for nicotine use disorders- Local > Topical > Transdermal patch: 5 to 30 mg per 16 hour; 7 to 21 mg per 24 hour
- Oral > Solid > lozenge: 2 mg; 4 mg lozenge
- Local > Buccal > Oral spray: 1 mg per actuation
- Local > Buccal > Chewing gum: 2 mg; 4 mg
Indications -
Nifedipine Informations générales
SectionAntioxytocics (tocolytics)- Oral > Solid: 10 mg (immediate-release)
Indications -
Nifurtimox Informations générales
SectionAmerican trypanosomiasis- Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)
IndicationsSectionMedicines for the treatment of 2nd stage African trypanosomiasis- Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)
Indications -
Nilotinib Informations générales
SectionTargeted therapies- Oral > Solid > capsule: 150 mg; 200 mg
-
Nilutamide Informations générales
SectionHormones and antihormonesIndicationsTherapeutic equivalent to bicalutamide pour Malignant neoplasms of prostate -
Nitrofurantoin Informations générales
SectionAccess group antibiotics- Oral > Liquid: 25 mg per 5 mL oral liquid
- Oral > Solid > dosage form: 100 mg; 50 mg
-
Nitrous oxide Informations générales
SectionGeneral anaesthetics and oxygen > Inhalational medicines- Respiratory > Inhalation:
Indications -
Nivolumab Informations générales
SectionImmunomodulators- Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion
Indications -
Norethisterone Informations générales
SectionProgestogensIndicationsTherapeutic equivalent to medroxyprogesterone acetate pour Excessive menstruation with irregular cycle -
Norethisterone enantate Informations générales
SectionInjectable hormonal contraceptives- Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule oily solution
-
Normal immunoglobulin Informations générales
SectionHuman immunoglobulins- Parenteral > General injections > IV: 5% protein solution; 10% protein solution
- Parenteral > General injections > IM: 16% protein solution
- Parenteral > General injections > SC: 15% protein solution; 16% protein solution
-
Nystatin Informations générales
SectionAntifungal medicines- Oral > Liquid: 100000 IU per mL
- Local > Topical > Other: 100000 IU pessary
- Oral > Solid > dosage form: 500000 IU
- Oral > Solid > lozenge: 100000 IU
Indications -
Octreotide Informations générales
SectionMedicines for disorders of the pituitary hormone system- Parenteral > General injections > IM: 20 mg in vial (modified-release, as acetate) plus diluent
- Parenteral > General injections > SC: 0.05 mg per mL in 1 mL vial (immediate-release, as acetate); 0.1 mg per mL in 1 mL vial (immediate-release, as acetate); 0.5 mg per mL in 1 mL vial (immediate-release, as acetate)
Indications -
Ofloxacin Informations générales
SectionEar, nose and throat medicines [c]IndicationsTherapeutic equivalent to ciprofloxacin pour Infectious diseases of external earSectionOphthalmological preparations > Anti-infective agents- Local > Ophthalmological > Solution (eye drops): 0.3%
Indications -
Olanzapine Informations générales
SectionMedicines for psychotic disorders- Parenteral > General injections > IM: 10 mg in vial powder for injection
IndicationsTherapeutic equivalent to risperidone pour Schizophrenia or other primary psychotic disorders Schizophrenia or other primary psychotic disorders -
Omeprazole Informations générales
SectionAntiulcer medicines- Oral > Liquid: 20 mg powder for oral liquid; 40 mg powder for oral liquid
- Oral > Solid: 10 mg; 20 mg; 40 mg
- Parenteral > General injections > IV: 40 mg in vial
-
Ondansetron Informations générales
SectionMedicines for other common symptoms in palliative care- Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (ondansetron base, as hydrochloride)
- Oral > Liquid: 4 mg per 5 mL (ondansetron base)
- Oral > Solid: 4 mg (ondansetron base); 8 mg (ondansetron base)
IndicationsSectionAntiemetic medicines- Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (ondansetron base, as hydrochloride)
- Oral > Liquid: 4 mg per 5 mL (ondansetron base)
- Oral > Solid: 4 mg (ondansetron base); 8 mg (ondansetron base); 24 mg (ondansetron base)
Indications -
Oral rehydration salts Informations générales
SectionOral rehydration- Powder for dilution in 200 mL, 500 mL, 1 L:
- - glucose 75 mEq
- - sodium 75 mEq or mmol/L
- - chloride 65 mEq or mmol/L
- - potassium 20 mEq or mmol/L
- - citrate 10 mmol/L
- - osmolarity 245 mOsm/L
- - glucose 13.5 g/L
- - sodium chloride 2.6 g/L
- - potassium chloride 1.5 g/L
- - trisodium citrate dihydrate 2.9 g/L
IndicationsSectionSolutions correcting water, electrolyte and acid-base disturbances > Oral- Powder for dilution in 200 mL, 500 mL, 1 L:
- - glucose 75 mEq
- - sodium 75 mEq or mmol/L
- - chloride 65 mEq or mmol/L
- - potassium 20 mEq or mmol/L
- - citrate 10 mmol/L
- - osmolarity 245 mOsm/L
- - glucose 13.5 g/L
- - sodium chloride 2.6 g/L
- - potassium chloride 1.5 g/L
- - trisodium citrate dihydrate 2.9 g/L
-
Oral rehydration salts - zinc sulfate Informations générales
SectionMedicines used in diarrhoea- Oral > Other: ORS powder for dilution and zinc sulfate solid oral dosage form 20 mg (co-packaged)
Indications -
Oseltamivir Informations générales
SectionOther antivirals- Oral > Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate); 75 mg capsule (as phosphate)
-
Oxaliplatin Informations générales
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial
-
Oxamniquine Informations générales
SectionAntischistosomals and other antitrematode medicines- Oral > Liquid: 250 mg per 5 mL
- Oral > Solid > capsule: 250 mg
Indications -
Oxycodone Informations générales
-
Oxygen Informations générales
SectionGeneral anaesthetics and oxygen > Inhalational medicines- Respiratory > Inhalation: (medical gas)
IndicationsSectionMedical gases- Respiratory > Inhalation:
Indications -
Oxytetracycline Informations générales
SectionOphthalmological preparations > Anti-infective agentsIndicationsTherapeutic equivalent to tetracycline pour Other specified conjunctivitis Therapeutic equivalent to tetracycline pour Infectious keratitis Therapeutic equivalent to tetracycline pour Infectious blepharitis Therapeutic equivalent to tetracycline pour Trachoma -
Oxytocin Informations générales
SectionUterotonics- Parenteral > General injections > unspecified: 10 IU per mL
Indications -
P-aminosalicylate sodium Informations générales
SectionAntituberculosis medicines- Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid) powder for oral solution
Indications -
Paclitaxel Informations générales
SectionCytotoxic medicines- Parenteral > General injections > IV: 6 mg per mL
IndicationsOther specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of nasopharynx Kaposi sarcoma of unspecified primary site Other specified malignant neoplasms of breast Other specified carcinomas of ovary Malignant neoplasms of breast Malignant neoplasms of cervix uteri -
Paliperidone Informations générales
SectionMedicines for psychotic disorders- Parenteral > General injections > IM: 25 mg in pre-filled syringe (as palmitate); 50 mg in pre-filled syringe (as palmitate); 75 mg in pre-filled syringe (as palmitate); 100 mg in pre-filled syringe (as palmitate); 150 mg in pre-filled syringe (as palmitate)
IndicationsTherapeutic equivalent to risperidone pour Schizophrenia or other primary psychotic disorders Schizophrenia or other primary psychotic disorders -
Palonosetron Informations générales
SectionMedicines for other common symptoms in palliative careIndicationsTherapeutic equivalent to ondansetron pour Palliative careSectionAntiemetic medicinesIndicationsTherapeutic equivalent to ondansetron pour Nausea or vomiting -
Pancreatic enzymes Informations générales
SectionPancreatic enzymes- Oral > Solid: Age-appropriate formulations and doses including lipase, protease and amylase.
Indications -
Paracetamol (acetaminophen) Informations générales
SectionNon-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)- Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL
- Local > Rectal > Suppository: 100 mg; 250 mg
- Oral > Solid > dispersible tablet: 100 mg; 250 mg
- Oral > Solid > tablet: 250 mg; 325 mg; 500 mg
IndicationsSectionAntimigraine medicines > For treatment of acute attack- Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL
- Local > Rectal > Suppository: 250 mg
- Oral > Solid > dispersible tablet: 100 mg; 250 mg
- Oral > Solid > tablet: 250 mg; 325 mg; 500 mg
Indications -
Paromomycin Informations générales
SectionAntileishmaniasis medicines- Parenteral > General injections > IM: 750 mg paromomycin base (as sulfate)
Indications -
Pegaspargase Informations générales
SectionCytotoxic medicines- Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection
Indications -
Pegfilgrastim Informations générales
SectionImmunomodulators- Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe
Indications -
Pembrolizumab Informations générales
SectionImmunomodulatorsIndicationsTherapeutic equivalent to nivolumab pour Melanoma of skin -
Penicillamine Informations générales
SectionAntidotes and other substances used in poisonings > Specific- Oral > Solid: 250 mg
SectionDisease-modifying anti-rheumatic drugs (DMARDs)- Oral > Solid: 250 mg
Indications -
Pentamidine Informations générales
SectionMedicines for the treatment of 1st stage African trypanosomiasis- Parenteral > General injections > IM: 300 mg in vial (as isetionate) powder for injection
IndicationsSectionAntipneumocystosis and antitoxoplasmosis medicines- Oral > Solid > tablet: 200 mg (as isethionate); 300 mg (as isethionate)
Indications -
Permethrin Informations générales
SectionDermatological medicines > Scabicides and pediculicides- Local > Topical > Lotion: 1%
- Local > Topical > Cream: 5%
Indications -
Pertussis vaccine Informations générales
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Phenobarbital Informations générales
SectionAntiseizure medicines- Oral > Liquid: 15 mg per 5 mL
- Oral > Solid: 15 to 100 mg
- Parenteral > General injections > IV: 200 mg per mL (phenobarbital sodium); 30 mg per mL (phenobarbital sodium); 60 mg per mL (phenobarbital sodium)
Indications -
Phenoxymethylpenicillin Informations générales
SectionAccess group antibiotics- Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid
- Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)
-
Phenytoin Informations générales
SectionAntiseizure medicines- Oral > Liquid: 30 mg per 5 mL (phenytoin)
- Parenteral > General injections > unspecified: 50 mg per mL in vial (phenytoin sodium)
- Oral > Solid > tablet: 50 mg (phenytoin) (chewable)
- Oral > Solid > dosage form: 25 mg (phenytoin sodium); 50 mg (phenytoin sodium); 100 mg (phenytoin sodium)
Indications -
Phytomenadione Informations générales
SectionMedicines affecting coagulation- Parenteral > General injections > IV: 10 mg per mL in ampoule; 1 mg per mL in ampoule
- Oral > Solid: 10 mg tablet
-
Pilocarpine Informations générales
SectionOphthalmological preparations > Miotics and antiglaucoma medicines- Local > Ophthalmological > Solution (eye drops): 2% (hydrochloride or nitrate); 4% (hydrochloride or nitrate)
-
Piperacillin + tazobactam Informations générales
SectionWatch group antibiotics- Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection
Indications -
Platelets Informations générales
SectionBlood and blood components- Parenteral > General injections > IV:
Indications -
Plazomicin Informations générales
SectionReserve group antibiotics- Parenteral > General injections > IV: 500 mg per 10 mL
-
Pneumococcal vaccine Informations générales
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
-
Podophyllotoxin Informations générales
SectionDermatological medicines > Medicines affecting skin differentiation and proliferationIndicationsTherapeutic equivalent to podophyllum resin pour Anogenital warts Therapeutic equivalent to podophyllum resin pour Plantar warts -
Podophyllum resin Informations générales
SectionDermatological medicines > Medicines affecting skin differentiation and proliferation- Local > Topical > Solution: 10 to 25%
Indications -
Poliomyelitis vaccine Informations générales
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Polygeline Informations générales
SectionPlasma substitutes- Parenteral > General injections > IV: 3.5% injectable solution
IndicationsTherapeutic equivalent to dextran 70 pour Hypovolaemia -
Polymyxin B (injection) Informations générales
SectionReserve group antibiotics- Parenteral > General injections > IV: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)
-
Potassium chloride Informations générales
SectionSolutions correcting water, electrolyte and acid-base disturbances > Oral- Oral > Liquid: powder for solution
IndicationsSectionSolutions correcting water, electrolyte and acid-base disturbances > Parenteral- Parenteral > General injections > IV: 11.2% in 20 mL ampoule (equivalent to K+ 1.5 mmol/mL and Cl- 1.5 mmol/mL); 7.5% solution for dilution (equivalent to K+ 1 mmol/mL and Cl- 2 mmol/mL); 15% solution for dilution (equivalent to K+ 2 mmol/mL and Cl- 2 mmol/mL)
Indications -
Potassium ferric hexacyanoferrate (Prussian blue) Informations générales
SectionAntidotes and other substances used in poisonings > Specific- Oral > Solid: Powder for oral administration
-
Potassium iodide Informations générales
SectionAntifungal medicines- Local > Topical > Solution: Saturated solution
IndicationsSectionThyroid hormones and antithyroid medicines- Oral > Solid: 60 mg
Indications -
Potassium permanganate Informations générales
SectionDermatological medicines > Anti-infective medicines- Local > Topical > Solution: aqueous solution: 1:10 000
-
Povidone iodine Informations générales
SectionAntiseptics- Local > Topical > Solution: 10% (equivalent to 1% available iodine)
Indications -
Pravastatin Informations générales
SectionLipid-lowering agentsIndicationsTherapeutic equivalent to simvastatin pour Mixed hyperlipidaemia Therapeutic equivalent to simvastatin pour Coronary atherosclerosis -
Praziquantel Informations générales
SectionAntischistosomals and other antitrematode medicines- Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg
IndicationsSectionIntestinal anthelminthics- Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg
SectionCysticidal medicines- Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg
Indications -
Precipitated sulfur Informations générales
SectionDermatological medicines > Scabicides and pediculicides- Local > Topical > Ointment:
IndicationsTherapeutic equivalent to benzyl benzoate pour Pthiriasis Therapeutic equivalent to benzyl benzoate pour Pediculosis corporis Therapeutic equivalent to benzyl benzoate pour Pediculosis capitis Therapeutic equivalent to benzyl benzoate pour Scabies -
Prednisolone Informations générales
SectionAnti-inflammatory medicines- Local > Rectal > Retention enema:
- Local > Rectal > Retention enema: 20 mg per 100 mL (as sodium phosphate)
IndicationsTherapeutic equivalent to hydrocortisone pour Crohn disease site Crohn disease site Ulcerative colitisSectionHormones and antihormones- Oral > Solid: 5 mg; 25 mg
- Oral > Liquid: 5 mg per mL
IndicationsPlasma cell myeloma Follicular lymphoma Lymphoid leukaemia, not elsewhere classified Malignant neoplasms of prostate Chronic lymphocytic leukaemia or small lymphocytic lymphoma Hodgkin lymphoma Diffuse large B-cell lymphomas Burkitt lymphoma including Burkitt leukaemia Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosisSectionAntiallergics and medicines used in anaphylaxis- Oral > Liquid: 5 mg per mL
- Oral > Solid: 5 mg; 25 mg
SectionOphthalmological preparations > Anti-inflammatory agents- Local > Ophthalmological > Solution (eye drops): 0.5% (sodium phosphate)
Indications -
Prednisone Informations générales
SectionHormones and antihormonesIndicationsTherapeutic equivalent to prednisolone pour Plasma cell myeloma Therapeutic equivalent to prednisolone pour Follicular lymphoma Therapeutic equivalent to prednisolone pour Lymphoid leukaemia, not elsewhere classified Therapeutic equivalent to prednisolone pour Malignant neoplasms of prostate Therapeutic equivalent to prednisolone pour Chronic lymphocytic leukaemia or small lymphocytic lymphoma Therapeutic equivalent to prednisolone pour Hodgkin lymphoma Therapeutic equivalent to prednisolone pour Diffuse large B-cell lymphomas Therapeutic equivalent to prednisolone pour Anaplastic large cell lymphoma, ALK-negative Therapeutic equivalent to prednisolone pour Anaplastic large cell lymphoma, ALK-positive Therapeutic equivalent to prednisolone pour Langerhans cell histiocytosisSectionAntiallergics and medicines used in anaphylaxisIndicationsTherapeutic equivalent to prednisolone pour Allergic or hypersensitivity conditions of unspecified type -
Pretomanid Informations générales
SectionAntituberculosis medicines- Oral > Solid > tablet: 200 mg
Indications -
Primaquine Informations générales
SectionAntimalarial medicines > For curative treatment- Oral > Solid: 7.5 mg tablet (as phosphate); 15 mg tablet (as phosphate)
-
Procaine benzylpenicillin Informations générales
SectionAccess group antibiotics- Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection
-
Procarbazine Informations générales
SectionCytotoxic medicines- Oral > Solid > capsule: 50 mg (as hydrochloride)
Indications -
Progesterone vaginal ring Informations générales
SectionIntravaginal contraceptives- Local > Vaginal > vaginal ring: 2.074 g micronized progesterone
-
Proguanil Informations générales
SectionAntimalarial medicines > For chemoprevention- Oral > Solid: 100 mg tablet (hydrochloride)
Indications -
Propanol Informations générales
SectionAntisepticsIndicationsTherapeutic equivalent to ethanol pour Denatured alcohol -
Propofol Informations générales
SectionGeneral anaesthetics and oxygen > Injectable medicines- Parenteral > General injections > IV: 10 mg per mL; 20 mg per mL
Indications -
Propranolol Informations générales
SectionAntimigraine medicines > For prophylaxis- Oral > Solid: 40 mg tablet (hydrochloride); 20 mg tablet (hydrochloride)
Indications -
Propylthiouracil Informations générales
SectionThyroid hormones and antithyroid medicines- Oral > Solid: 50 mg
Indications -
Prostaglandin E1 Informations générales
SectionMedicines administered to the neonate [c]- Parenteral > General injections > IV: 0.5 mg per mL in alcohol
-
Prostaglandin E2 Informations générales
SectionMedicines administered to the neonate [c]- Parenteral > General injections > IV: 1 mg per mL
IndicationsTherapeutic equivalent to prostaglandin E1 pour Other specified congenital anomaly of great arteries including arterial duct -
Protamine sulfate Informations générales
SectionMedicines affecting coagulation- Parenteral > General injections > IV: 10 mg per mL in 5 mL ampoule
-
Protionamide Informations générales
SectionAntituberculosis medicinesIndicationsTherapeutic equivalent to ethionamide pour Multi-drug resistant Mycobacterium tuberculosis -
Pyrantel Informations générales
SectionIntestinal anthelminthics- Oral > Solid > tablet: 250 mg (chewable) (as embonate or pamoate)
Indications -
Pyrazinamide Informations générales
SectionAntituberculosis medicines- Oral > Solid > dispersible tablet: 150 mg
- Oral > Solid > tablet: 400 mg; 500 mg
Indications -
Pyridostigmine Informations générales
SectionMuscle relaxants (peripherally-acting) and cholinesterase inhibitors- Parenteral > General injections > IV: 1 mg in 1 mL ampoule (pyridostigmine bromide)
- Oral > Solid: 60 mg (pyridostigmine bromide)
Indications -
Pyridoxine Informations générales
SectionVitamins and minerals- Oral > Solid: 25 mg (hydrochloride)
-
Pyrimethamine Informations générales
SectionAntipneumocystosis and antitoxoplasmosis medicines- Oral > Solid: 25 mg
Indications -
Quetiapine Informations générales
SectionMedicines for psychotic disordersIndicationsTherapeutic equivalent to risperidone pour Schizophrenia or other primary psychotic disordersSectionMedicines for bipolar disorders- Oral > Solid > tablet: 25 mg (immediate-release); 100 mg (immediate-release); 150 mg (immediate-release); 200 mg (immediate-release); 300 mg (immediate-release); 50 mg (modified-release); 150 mg (modified-release); 200 mg (modified-release); 300 mg (modified-release); 400 mg (modified-release)
Indications -
Quinine Informations générales
SectionAntimalarial medicines > For curative treatment- Parenteral > General injections > IV: 300 mg per mL in 2 mL ampoule (quinine hydrochloride)
- Oral > Solid: 300 mg (quinine sulfate or quinine bisulfate)
Indications -
Rabies vaccine Informations générales
SectionRecommendations for some high-risk populations- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Raltegravir Informations générales
SectionAntiretrovirals > Integrase inhibitors- Oral > Liquid: 100 mg granules for oral suspension
- Oral > Solid: 400 mg tablet; 25 mg tablet (chewable)
-
Ranitidine Informations générales
SectionAntiulcer medicines- Oral > Liquid: 75 mg per 5 mL (as hydrochloride)
- Oral > Solid: 150 mg (as hydrochloride)
- Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (as hydrochloride)
-
Rasburicase Informations générales